PATH: Form 990, tax year 2016

View the entire original 990 at ProPublica ↗

Organization: PATH (EIN 91-1157127)
Tax period: 2016-01-01 to 2016-12-31
Filed: 2017-11-14
IRS object ID: 201733189349304943
Schema version: 2016v3.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2017-11-14T12:37:00-06:00	ReturnTs
Tax Period End	2016-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	521392008	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	GELMAN ROSENBERG & FREEDMAN	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	4550 MONTGOMERY AVE SUITE 650N	AddressLine1Txt
City	BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	208142930	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2016-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	911157127	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PATH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	PATH	BusinessNameControlTxt
Phone	2062853500	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVENUE NO 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	OLIVIA D POLIUS	PersonNm
Person Title	CHIEF FINANCIAL OFFICER	PersonTitleTxt
Phone	2062853500	PhoneNum
Signature	2017-11-14	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Phone	3019519090	PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	75.103.231.202	IPv4AddressTxt

Field	Value	IRS element (for citing)
IP	2017-11-14	IPDt
IP Tm	13:36:34	IPTm
IP Timezone	ES	IPTimezoneCd
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	24E2B1EDDFB7997E904F8C8AA54720A5F314F67A	AtSubmissionCreationDeviceId
At Submission Filing Device Id	1C84E1F40D0AB4F75A6C29AABE8087358D4F1C89	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2016	TaxYr
Build TS	2017-02-10 21:41:12Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	STEPHEN B DAVIS	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVENUE NO 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$364,644,480	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.PATH.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1981	FormationYr
Legal Domicile State	WA	LegalDomicileStateCd
Activity Or Mission	SEE PART III, LINE 1.	ActivityOrMissionDesc
Voting Members Governing Body	16	VotingMembersGoverningBodyCnt
Voting Members Independent	15	VotingMembersIndependentCnt
Total Employee	783	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$243,499,792	PYContributionsGrantsAmt
CY Contributions Grants	$298,315,988	CYContributionsGrantsAmt
PY Program Service Revenue	$24,796	PYProgramServiceRevenueAmt
CY Program Service Revenue	$29,465	CYProgramServiceRevenueAmt
PY Investment Income	$1,908,636	PYInvestmentIncomeAmt
CY Investment Income	$1,742,492	CYInvestmentIncomeAmt
PY Other Revenue	$2,513,804	PYOtherRevenueAmt
CY Other Revenue	$4,668,393	CYOtherRevenueAmt
PY Total Revenue	$247,947,028	PYTotalRevenueAmt
CY Total Revenue	$304,756,338	CYTotalRevenueAmt
PY Grants And Similar Paid	$61,297,455	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$67,139,518	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$110,366,669	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$122,728,502	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$4,138,731	CYTotalFundraisingExpenseAmt
PY Other Expenses	$91,916,808	PYOtherExpensesAmt
CY Other Expenses	$116,152,150	CYOtherExpensesAmt
PY Total Expenses	$263,580,932	PYTotalExpensesAmt
CY Total Expenses	$306,020,170	CYTotalExpensesAmt
PY Revenues Less Expenses	-$15,633,904	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$1,263,832	CYRevenuesLessExpensesAmt
Total Assets BOY	$458,736,625	TotalAssetsBOYAmt
Total Assets EOY	$450,940,286	TotalAssetsEOYAmt
Total Liabilities BOY	$47,244,164	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$53,692,915	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$411,492,461	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$397,247,371	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	PATH'S MISSION IS TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD BY ADVANCING TECHNOLOGIES, STRENGTHENING SYSTEMS, AND ENCOURAGING HEALTHY BEHAVIORS. (CONTINUED ON SCHEDULE O)	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$83,226,259	ExpenseAmt
Grant	$15,050,921	GrantAmt
Revenue	$5,365	RevenueAmt
Desc	PUBLIC HEALTH: PATH'S PUBLIC HEALTH PORTFOLIO TOUCHES ON THREE PRIMARY AREAS. FIRST, WE WORK TO COMBAT INFECTIOUS DISEASES, WITH A FOCUS ON MALARIA, HIV/AIDS, TUBERCULOSIS (TB), AND NTDS. WE ALSO WORK TO SUPPORT THE HEALTH OF KEY POPULATIONS-INCLUDING NEWBORNS, CHILDREN, ADOLESCENTS, AND MOTHERS-AND TO IMPROVE WOMEN'S HEALTH AND SEXUAL AND REPRODUCTIVE HEALTH (SRH). FINALLY, WE TARGET EMERGING ISSUES THROUGH OUR DIGITAL HEALTH SOLUTIONS, NONCOMMUNICABLE DISEASES (NCDS), NUTRITION INNOVATION, AND HEALTH SYSTEMS STRENGTHENING AND EPIDEMIC PREPAREDNESS WORK.MALARIA:MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. THEY PARTNER WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS WORLDWIDE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE THAT OUR PROGRAMS ARE SUSTAINABLE AND EFFICACIOUS. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS TOWARD CONTROLLING AND ELIMINATING MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2016, THE MALARIACARE PARTNERSHIP, WHICH PATH LEADS, CONTINUED TO STRENGTHEN HEALTH SYSTEMS AND IMPROVE THE QUALITY OF MALARIA CASE MANAGEMENT IN 17 COUNTRIES IN AFRICA AND THE MEKONG REGION. ADDITIONALLY, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA IN THEIR MALARIA ELIMINATION GOALS BY SCALING UP PREVENTION AND TREATMENT, ADVANCING SENSITIVE DIAGNOSTIC TOOLS, ESTABLISHING RAPID REPORTING SYSTEMS, AND TESTING NEW APPROACHES (SUCH AS MASS DRUG ADMINISTRATION). PATH ALSO CONTINUED EFFORTS TO IMPROVE DATA FOR MALARIA CONTROL DECISION-MAKING AND SURVEILLANCE. IN ZAMBIA, THE VISUALIZE NO MALARIA PROJECT-A GROUNDBREAKING PARTNERSHIP WITH A SEATTLE-BASED SOFTWARE COMPANY AND A COALITION OF OTHER TECHNOLOGY COMPANIES-CONTINUED TO EXPAND. THIS PROJECT EQUIPS HEALTH WORKERS AND OFFICIALS WITH THE REAL-TIME DATA VISUALIZATION TOOLS THEY NEED TO SEE AND UNDERSTAND WHERE MALARIA IS APPEARING SO THAT THEY CAN APPROPRIATELY DEPLOY RESOURCES TO HALT ITS SPREAD. THIS YEAR, PATH MADE STRIDES TOWARD THE NEXT GENERATION OF TOOLS TO DETECT, PREVENT, AND TREAT MALARIA. AS NOTED ABOVE, AFTER DECADES OF RESEARCH AND TESTING, IN 2016 THE WORLD'S FIRST MALARIA VACCINE CANDIDATE, RTS,S, WHICH PATH HELPED TO DEVELOP, RECEIVED APPROVAL FROM EUROPEAN REGULATORS AND FROM WHO FOR PILOT INTRODUCTION IN AFRICA. PATH ALSO SUPPORTED THE DEVELOPMENT OF A NEW, HIGHLY SENSITIVE RAPID DIAGNOSTIC TEST THAT OFFERS A GREATER THAN TENFOLD IMPROVEMENT IN DETECTION OF THE MOST COMMON MALARIA PARASITE. WE ALSO ADVANCED WORK ON A POINT-OF-CARE DIAGNOSTIC TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE MALARIA TREATMENT. COMBATING HIV/AIDS:IN 2016, OUR EFFORTS TO REDUCE THE GLOBAL BURDEN OF HIV/AIDS CONTINUED TO FOCUS ON THE UNIQUE NEEDS OF MARGINALIZED AND HARD-TO-REACH GROUPS, INCLUDING ADOLESCENT GIRLS AND YOUNG WOMEN, ORPHANS AND VULNERABLE CHILDREN, PEOPLE CO-INFECTED WITH HIV AND TB, SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, AND PEOPLE WHO INJECT DRUGS. TO IMPROVE HIV DIAGNOSTICS, WE FOCUSED ON ADVANCING ACCESSIBLE AND AFFORDABLE PRODUCTS TO FILL GAPS IN SELF-TESTING, EARLY INFANT DIAGNOSIS AND TREATMENT, VIRAL LOAD DETECTION, AND MONITORING FOR DRUG RESISTANCE. PATH ALSO ADVANCED ALTERNATIVE AND LOW-COST METHODS TO DELIVER MICROBICIDES AND ANTIRETROVIRAL MEDICATIONS (ARVS) FOR HIV PREVENTION AND TREATMENT, INCLUDING A PEDIATRIC-FRIENDLY ARV DOSAGE FORMULATION.THROUGH THE AIDS POPULATION AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS) IN WESTERN KENYA, PATH HELPED TO INTEGRATE SERVICES FOR HIV/AIDS, SRH, TB, NCDS, AND OTHER ILLNESSES TO HELP MORE PEOPLE ACCESS A GREATER SPECTRUM OF SERVICES. WITH SUPPORT FROM THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF DREAMS INITIATIVE, APHIAPLUS INTENSIFIED EFFORTS TO REACH ADOLESCENT GIRLS AND YOUNG WOMEN IN TWO COUNTIES WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES. PATH WAS ALSO SELECTED TO IMPLEMENT A FIRST-OF-ITS-KIND PROGRAM TO INTEGRATE HYPERTENSION SCREENING AND CARE INTO THE HIV/AIDS SERVICE DELIVERY PLATFORM IN KENYA. AS 2016 BEGAN, DATA SHOWED THE SUBSTANTIAL REACH OF THIS AND OTHER EFFORTS. FOR EXAMPLE, THE NUMBER OF PEOPLE RETURNING TO APHIAPLUS WESTERN HEALTH FACILITIES FOR HIV TREATMENT (ANTIRETROVIRAL THERAPY)INCREASED FROM 55,752 TOTAL IN APRIL 2013 TO 95,763 TOTAL IN AUGUST 2016. IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), PATH LED A WIDE-REACHING HIV/AIDS PROJECT THAT SUPPORTED HEALTH FACILITIES AND HEALTH ZONES TO PROVIDE AN INTEGRATED PACKAGE OF HIV SERVICES. IN ADDITION, WE INTRODUCED INNOVATIONS TO REACH POPULATION GROUPS MOST AT RISK OF HIV INFECTION. IN VIETNAM, WE CONTINUED WORK TO GENERATE MARKETS FOR HIV PREVENTION PRODUCTS AND SERVICES, INCLUDING A LOCAL COMMERCIAL CONDOM MARKET. WE EQUIPPED GROUPS OPERATED BY MEMBERS OF KEY POPULATIONS TO GENERATE DEMAND FOR SERVICES AMONG THEIR PEERS. WE PILOTED NEW APPROACHES TO HELP CONTROL HIV, AND WE PREPARED FOR THE INTRODUCTION OF HIV PRE-EXPOSURE PROPHYLAXIS. IN SOUTH AFRICA, PATH WORKED WITH LESBIAN, GAY, BISEXUAL, TRANSGENDER (LGBT), AND INTERSEX COMMUNITY-BASED GROUPS TO IMPROVE PROVISION OF HIV SERVICES TO MEN WHO HAVE SEX WITH MEN. INNOVATIVE APPROACHES TO FIGHT TUBERCULOSIS:PATH BRINGS GLOBAL HEALTH EXPERTISE AND INNOVATIVE APPROACHES TO THE FIGHT AGAINST TB. IN INDIA, WE IMPLEMENTED THE PUBLIC PRIVATE INTERFACE AGENCY (PPIA) TO IMPROVE PRIVATE-SECTOR HEALTH CARE PROVIDERS' CONTRIBUTIONS TO TB CONTROL IN MUMBAI'S SLUMS. PATH AND INDIAN PARTNERS RECOGNIZED THAT MANY OF THE MOST VULNERABLE PEOPLE IN INDIA SEEK CARE FROM INFORMAL, OFTEN UNTRAINED PRIVATE HEALTH CARE PROVIDERS (SUCH AS TRADITIONAL HEALERS), WHO OFTEN CANNOT ACCURATELY DIAGNOSE OR TREAT TB. THE PPIA PROJECT RESPONDS BY LINKING THESE PROVIDERS TO BETTER-TRAINED PROVIDERS IN THE PRIVATE AND PUBLIC SECTORS. USING A VOUCHER MECHANISM, PPIA EMPOWERS INFORMAL PROVIDERS TO SEND THEIR PATIENTS, FREE OF CHARGE OR SUBSIDIZED, TO TB DIAGNOSTIC AND TREATMENT SERVICES. PPIA HAS DRAMATICALLY IMPROVED ACCESS TO SERVICES AND IS INCREASING PRIVATE PROVIDERS' CAPACITY TO ACCURATELY DIAGNOSE AND MANAGE TB. IN SOUTH AFRICA, PATH AND OUR PARTNERS DEVELOPED AND IMPLEMENTED A BEHAVIOR CHANGE COMMUNICATION INTERVENTION TO TRAIN HEALTH CARE WORKERS ON TB INFECTION PREVENTION AND CONTROL PRACTICES. IN VIETNAM, WE COLLABORATED WITH A PRIVATE-SECTOR PARTNER TO PILOT A MODEL TO STRENGTHEN CHILDHOOD TB CASE DETECTION, EARLY TREATMENT, AND MORE. IN TANZANIA, PATH TRAINED AND SUPPORTED TRADITIONAL HEALERS, PRIVATE DRUG SELLERS, COMMUNITY-BASED ORGANIZATIONS, AND FORMER TB PATIENTS TO DELIVER COMMUNITY-BASED TB INTERVENTIONS. IN A PROJECT TO IMPROVE TB CARE IN ETHIOPIA, PATH AND CONSORTIUM PARTNERS SUPPORTED HEALTH EXTENSION WORKERS AND COMMUNITY-BASED ORGANIZATIONS TO BUILD BETTER REFERRAL SYSTEMS, IMPROVE CASE DETECTION, AND INCREASE ADHERENCE TO TREATMENT.OUR CONTRIBUTIONS TO THE GLOBAL RESPONSE TO COMBAT MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) INCLUDED ESTABLISHING A "TEST AND REFER" MODEL IN THE PRIVATE SECTOR IN MUMBAI, INDIA, AND WORKING WITH LOCAL PARTNERS TO IMPLEMENT A PATIENT-CENTERED APPROACH TO MDR-TB CASE MANAGEMENT IN UKRAINE.MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION:PATH WORKS WITH PARTNERS TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION AROUND THE WORLD. TOGETHER, WE DEVELOP, ADAPT, AND SCALE TECHNOLOGIES AND APPROACHES TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN ALL OUR EFFORTS, WE WORK TO PUT THE LOCAL GOVERNMENT IN THE DRIVER'S SEAT TO ENSURE BOTH SCALE AND SUSTAINABILITY.IN 2016, PATH CONTINUED TO EXPAND OUR LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). RESEARCH HAS SHOWN THAT WHEN PARENTS AND CAREGIVERS PLAY AND TALK WITH CHILDREN IN THEIR EARLY YEARS, CHILDREN GROW UP TO BE HEALTHIER, MORE EDUCATED, AND MORE PRODUCTIVE ADULTS. YET TRADITIONAL CENTER-BASED ECD APPROACHES TEND TO TARGET OLDER CHILDREN. THIS MISSES THE CRITICAL WINDOW OF OPPORTUNITY WHEN THE BRAIN DEVELOPS MOST RAPIDLY AND DEVELOPMENTAL DELAYS MAY BE REVERSED. WITH PATH SUPPORT, THE GOVERNMENTS OF KENYA AND MOZAMBIQUE ARE INCLUDING ECD SERVICES IN BASIC HEALTH CARE FOR CAREGIVERS AND THEIR YOUNG CHILDREN. PATH'S APPROACH TO INTEGRATING ECD INTO THE HEALTH SYSTEM FOCUSES ON SUPPORTING AND BUILDING THE CAPACITY OF EXISTING HEALTH SERVICE PROVIDERS AND THEIR SUPERVISORS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$69,044,911	ExpenseAmt
Grant	$25,788,932	GrantAmt
Desc	ESSENTIAL MEDICINES: PATH IS A GLOBAL LEADER IN IDENTIFYING, DEVELOPING, AND INTRODUCING AFFORDABLE, EFFECTIVE, AND EASY-TO-USE ESSENTIAL MEDICINES, SUCH AS VACCINES AND DRUGS. WE WORK WITH GOVERNMENTS, NONGOVERNMENTAL ORGANIZATIONS, PRIVATE COMPANIES, EDUCATIONAL INSTITUTIONS, AND OTHER GROUPS TO SHEPHERD THESE INNOVATIONS ALL THE WAY FROM BRIGHT IDEA TO LARGE-SCALE USE.CENTER FOR VACCINE INNOVATION AND ACCESS:PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES GLOBALLY AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES (LMIC). OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILDHOOD DEATHS WORLDWIDE.FOR EXAMPLE, IN 2016 WE CONTINUED TO HELP COUNTRIES EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINE, WHICH PATH HELPED DEVELOP AND SHEPHERDED THROUGH THE GLOBAL REGULATORY PROCESS. WITH THE SUPPORT OF PATH, THE GOVERNMENT OF CAMBODIA LAUNCHED A NEW SERIES OF JE IMMUNIZATION CAMPAIGNS FOCUSED ON NEARLY 4.3 MILLION CHILDREN AGED 9 MONTHS TO 15 YEARS. NEPAL EXPANDED ITS JE PREVENTION AND CONTROL PROGRAM NATIONWIDE. PATH ALSO PUBLISHED AND DISSEMINATED A GUIDE TO HELP COUNTRY DECISION-MAKERS UNDERSTAND AND INTRODUCE THE VACCINE. AS OF 2016, THE JE VACCINE HAS REACHED 26.8 MILLION PEOPLE IN 11 COUNTRIES WORLDWIDE.WE EVALUATED THE LONG-TERM IMMUNE RESPONSE TO MENAFRIVAC , A LOW-COST VACCINE DEVELOPED BY PATH, THE WORLD HEALTH ORGANIZATION (WHO), AND INDIAN VACCINE MANUFACTURER SERUM INSTITUTE OF INDIA. THIS VACCINE PROTECTS CHILDREN AND YOUNG ADULTS FROM DEBILITATING AND OFTEN DEADLY SEROGROUP A MENINGOCOCCAL MENINGITIS. AS OF 2016, THE VACCINE HAS BEEN ADMINISTERED TO MORE THAN 270 MILLION PEOPLE IN 26 COUNTRIES, VIRTUALLY ELIMINATING MENINGITIS A IN THOSE AREAS. WITH OUR PARTNERS, WE ALSO INITIATED A PHASE 1 STUDY OF A VACCINE TO PROTECT AGAINST OTHER SEROGROUPS OF MENINGOCOCCAL MENINGITIS. [MENAFRIVAC IS A REGISTERED TRADEMARK OF SERUM INSTITUTE OF INDIA PVT. LTD.]TO STOP MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2016, FUNDING WAS SECURED FOR THE FIRST PHASE OF THE WHO-LED MALARIA VACCINE IMPLEMENTATION PROGRAM FOR THE RTS,S VACCINE CANDIDATE. PATH IS WORKING WITH WHO AND OTHER STAKEHOLDERS TO PREPARE FOR PILOT IMPLEMENTATION IN SELECTED REAL-LIFE SETTINGS IN GHANA, KENYA, AND MALAWI BEGINNING IN 2018. WITH PARTNERS, PATH IS ALSO ADVANCING RESEARCH INTO WHETHER, BY REDUCING AND DELAYING THE ADMINISTRATION OF VACCINE DOSES, RTS,S HAS THE POTENTIAL TO AID MALARIA ELIMINATION EFFORTS. OUR WORK TO COMBAT DIARRHEAL DISEASES, THE SECOND LEADING CAUSE OF DEATH AMONG CHILDREN IN LMIC, CONTINUED THIS YEAR. FOR EXAMPLE, WE PARTNERED WITH A PRIVATE INDIA-BASED COMPANY TO STUDY AND PROVIDE EVIDENCE FOR A NEW VACCINE AGAINST ONE COMMON CAUSE OF DIARRHEAL DISEASE, ROTAVIRUS. THE VACCINE COULD REMAIN STABLE AND POTENT EVEN DURING EXTENDED PERIODS WITHOUT REFRIGERATION, GIVING IT WIDER REACH. THE VACCINE ACHIEVED LICENSURE IN DECEMBER 2016. EARLIER IN THE YEAR, ROTAVAC, ANOTHER INDIAN-MADE VACCINE DEVELOPED WITH PATH SUPPORT, BEGAN ROLLOUT IN INDIA. [ROTAVAC IS A REGISTERED TRADEMARK OF BHARAT BIOTECH.]IN ADDITION, PATH CONDUCTED EARLY-STAGE CLINICAL TRIALS OF VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, LEADING CAUSES OF BACTERIAL DIARRHEAL ILLNESS. WE ALSO CONVENED A GLOBAL CONFERENCE THAT WAS THE FIRST TO BRING TOGETHER INTERNATIONAL LEADERS TO DISCUSS ETEC AND SHIGELLA AND ACCELERATE PROGRESS AGAINST THESE DISEASES. PATH'S DEFEAT DIARRHEAL DISEASE INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ONGOING WORK TO GENERATE INVESTMENTS IN ROTAVIRUS, ETEC, AND SHIGELLA VACCINES. A DATA VISUALIZATION PIECE AND INFOGRAPHIC ON LONG-TERM GUT DAMAGE ARE TWO EXAMPLES OF RESOURCES WE CREATED TO HELP ADVOCATES COMMUNICATE ABOUT THE LIFELONG CONSEQUENCES OF REPEATED INFECTIONS.WE ALSO ADVANCED DEVELOPMENT OF LOW-COST VACCINE CANDIDATES TO PROTECT CHILDREN AGAINST PNEUMOCOCCAL BACTERIA, THE TOP CAUSE OF SEVERE CHILDHOOD PNEUMONIA. IN THE GAMBIA, FOR INSTANCE, WE EVALUATED A PNEUMOCOCCAL CONJUGATE VACCINE CANDIDATE DESIGNED TO BE AFFORDABLE AND TO PROVIDE PROTECTION AGAINST THE TEN BACTERIAL SEROTYPES CAUSING THE MOST CASES OF INVASIVE PNEUMOCOCCAL DISEASE IN AFRICA AND ASIA. IN KENYA, PATH AND OUR PARTNERS STUDIED A VACCINE CANDIDATE WITH THE POTENTIAL TO PROVIDE LOW-COST, BROAD PROTECTION ACROSS MANY SEROTYPES. IN 2016, PATH BEGAN A PROJECT TO SUPPORT THE DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. THE INTENDED VACCINE POPULATION IS PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. WE ALSO ASSISTED THE GOVERNMENTS OF 16 LOW-RESOURCE COUNTRIES IN AFRICA AND ASIA TO PLAN, IMPLEMENT, AND EVALUATE THE USE OF A HUMAN PAPILLOMAVIRUS (HPV) VACCINE TO PROTECT AGAINST CERVICAL CANCER. FINALLY, WE COMPLETED WORK ON AN IMMUNIZATION DEMAND GENERATION PROJECT IN AFAR, ETHIOPIA, WHERE 19 PERCENT OF CHILDREN YOUNGER THAN FIVE YEARS ARE NOT IMMUNIZED AND ONE IN 16 CHILDREN DIE BEFORE THEIR FIFTH BIRTHDAY. WE COLLABORATED WITH GROUPS SUCH AS THE MINISTRY OF HEALTH (MOH), AFAR REGIONAL HEALTH BUREAU, AND REGIONAL ISLAMIC AFFAIRS OFFICE TO GENERATE GREATER VACCINE DEMAND AND COVERAGE.DRUG DEVELOPMENT:PATH AND OUR PARTNERS DEVELOP AND ADVANCE AFFORDABLE DRUGS TO PREVENT AND TREAT DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN LOW-INCOME COUNTRIES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES (NTDS), HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, AND NONPROFIT SECTORS, THIS WORK DEMONSTRATES THAT IT IS POSSIBLE TO REACH THE WORLD'S MOST VULNERABLE PEOPLE WITH THE MEDICINES THEY NEED. THIS YEAR, OUR WORK CONTINUED TO OVERTURN BARRIERS TO HEALTH AT EVERY STAGE OF DEVELOPMENT AND USE-FROM EARLY RESEARCH TO BROAD SCALE-UP.WE CONTINUED OUR WORK TO BREAK THE CYCLE OF SOIL-TRANSMITTED HELMINTH INFECTIONS. THESE INTESTINAL PARASITIC WORMS THRIVE IN AREAS WITH LIMITED SANITATION AND HYGIENE, WHERE THEY ARE TRANSMITTED THROUGH CONTACT WITH SOIL AND WATER CONTAMINATED BY THE PRACTICE OF OPEN DEFECATION. GLOBALLY, THEY AFFECT MORE THAN A BILLION PEOPLE. THROUGH A MULTIPRONGED APPROACH THAT INCLUDES DRUGS AND DIAGNOSTICS AS WELL AS IMPROVED SANITATION, PATH IS WORKING TO BREAK THE CYCLE OF CHRONIC INFECTIONS AND REDUCE THE BURDEN OF ILLNESS WORLDWIDE, INCLUDING OUR MOST RECENT COMMITMENT TO SEEK US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL FOR THE DRUG TRIBENDIMIDINE (TRBD) AS A SIGNIFICANTLY IMPROVED TREATMENT FOR HOOKWORM INFECTIONS. FDA APPROVAL IS THE INITIAL STEP IN A PLAN TO INCORPORATE TRBD INTO MASS DEWORMING CAMPAIGNS IN LOW-RESOURCE SETTINGS WHERE SOIL-TRANSMITTED HELMINTH INFECTIONS CAUSE SIGNIFICANT MORBIDITY. THE US$25 MILLION FINANCING OF PATH'S TRBD PROGRAM IS BEING LED BY A LEADING LIFE SCIENCES INVESTMENT FIRM, WITH PARTICIPATION FROM AN IMPACT INVESTMENT FUND FOCUSED ON NEGLECTED DISEASES AND MATERNAL AND CHILD HEALTH. OTHER PROJECTS INCLUDED WORKING WITH PARTNERS IN BANGLADESH TO CONVENE A NEW DIARRHEA INNOVATIONS GROUP, WHICH ALIGNS EXPERTS TO SHARE RESEARCH AND SPEED UP THE DEVELOPMENT AND ADOPTION OF NEW DIAGNOSTIC AND THERAPEUTIC TECHNOLOGIES FOR DIARRHEAL DISEASES. WE ALSO LED A GLOBAL SYMPOSIUM THAT CONVENED EXPERTS FROM ACROSS THE PUBLIC AND PRIVATE SECTORS TO ACCELERATE DEVELOPMENT OF NEW DRUGS TO TREAT CRYPTOSPORIDIUM INFECTION-A LEADING CAUSE OF DIARRHEAL DISEASE AMONG YOUNG CHILDREN.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$53,927,311	ExpenseAmt
Grant	$18,596,808	GrantAmt
Desc	INTERNATIONAL DEVELOPMENT: IN 2016, PATH'S INTERNATIONAL DEVELOPMENT PORTFOLIO SUPPORTED WORK IN MORE THAN 70 COUNTRIES, RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTI-COUNTRY EFFORTS. EXAMPLES OF OUR 2016 INTERNATIONAL DEVELOPMENT WORK ARE BELOW, FOCUSING ON INDIA, VIETNAM, AND ZAMBIA.IN INDIA, PATH WORKED WITH THE MINISTRY OF HEALTH AND FAMILY WELFARE (MOHFW), THE INDIAN COUNCIL OF MEDICAL RESEARCH, REGULATORS, VACCINE MANUFACTURERS, MEDICAL RESEARCH ORGANIZATIONS, PRIVATE PHYSICIANS, AND OTHER PARTNERS TO ACHIEVE KEY HEALTH WINS. WITH THE MOHFW AND TECHNICAL LEADERS, WE GUIDED WORK TO BUILD EVIDENCE-BACKED GUIDELINES FOR HUMAN MILK BANKING. PATH ALSO SUPPORTED THE FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA TO LAUNCH COMPREHENSIVE REGULATIONS TO GUIDE THE NUTRITIONAL FORTIFICATION OF FOOD. PATH PLAYED A PIVOTAL ROLE IN INTEGRATING FORTIFIED RICE INTO THE MIDDAY MEAL OF 2,600 SCHOOLS IN THREE DISTRICTS OF THE STATE OF KARNATAKA, AND WILL BEGIN WORK WITH OTHER STATE GOVERNMENTS TO FURTHER EXPAND FOOD FORTIFICATION. WITH AN INDIAN MANUFACTURER WE SUCCESSFULLY COMPLETED ANALYSIS OF A PHASE 3 EFFICACY STUDY OF A PENTAVALENT BOVINE-HUMAN REASSORTANT ROTAVIRUS VACCINE (BRV-PV) AGAINST ROTAVIRUS, A LEADING CAUSE OF SEVERE DIARRHEAL DISEASE. IN ADDITION, THE BRV-PV ROTAVIRUS VACCINE "ROTASIIL" OBTAINED MARKETING AUTHORIZATION FROM THE DRUGS CONTROLLER GENERAL OF INDIA. PATH WAS ALSO INVOLVED IN ADVANCING ANOTHER INDIAN-MADE ROTAVAC VACCINE (THE FIRST INDIAN ROTAVIRUS VACCINE). FIRST LICENSED IN 2014, THE VACCINE WAS INTRODUCED IN FOUR STATES; IN 2016, THE GOVERNMENT BEGAN TO EXPAND USE INTO FIVE MORE STATES.TO FIGHT ACUTE ENCEPHALITIS SYNDROME (AES) IN THE STATES OF UTTAR PRADESH AND BIHAR, PATH AND PARTNERS CONVENED TECHNICAL SUPPORT GROUPS TO STRENGTHEN HEALTH FACILITIES SO THEY CAN SERVE AS TREATMENT CENTERS. EARLY MANAGEMENT OF AES CAN PREVENT DEATH AND PERMANENT DISABILITY. PATH ALSO BUILT MEDICAL AND PARAMEDICAL STAFF CAPACITY TO IDENTIFY, REFER, DIAGNOSE, AND MANAGE AES CASES AND HELPED TO GENERATE COMMUNITY AWARENESS ON PREVENTION AND CONTROL. WE WORKED WITH THE GOVERNMENT TO STRENGTHEN DATA COLLECTION TO SUPPORT EVIDENCE-BASED PLANNING AND QUALITY IMPROVEMENT.TO COMBAT TB, PATH'S INNOVATIVE PPIA WORKED WITH COMMUNITIES, MUNICIPAL CORPORATIONS, AND PRIVATE PHYSICIANS TO SUCCESSFULLY INCREASE TB CASE NOTIFICATION AND REFERRAL RATES IN MUMBAI. THE SUCCESS OF THE INITIATIVE IN MUMBAI HAS LED TO ITS INCLUSION IN THE GOVERNMENT'S NATIONAL STRATEGIC PLAN. PPIA WILL SOON BE REPLICATED IN OTHER PARTS OF THE COUNTRY.PATH CONTINUED TO RUN A CLINICAL TRIAL TRAINING AND MENTORSHIP PROGRAM IN INDIA WITH THE AIM OF STRENGTHENING CLINICAL RESEARCH CAPACITY. IN 2016, PATH ALSO COLLABORATED WITH THE MOHFW TO LAUNCH PILOT TESTS OF NEW COLD CHAIN EQUIPMENT IN FOUR STATES. THE GOAL WAS TO FIND NEW, EFFICIENT METHODS TO KEEP HEAT-SENSITIVE VACCINES AND MEDICINES COLD AS THEY MOVE THROUGH THE PUBLIC HEALTH SUPPLY CHAIN. PATH IS SUPPORTING THE DESIGN OF AN INNOVATIVE, DURABLE LINER THAT CAN BE PLACED IN TRANSPORTATION COOLERS TO PROTECT VACCINES FROM FREEZING WHEN WORKERS USE FROZEN ICE PACKS. PATH HAS WORKED WITH THREE INDIAN MANUFACTURERS TO ADVANCE THE FREEZE-FREE DESIGN AND IS SUPPORTING THEM IN TESTING AND COMMERCIALIZING THE TECHNOLOGY.IN 2016, PATH'S INDIA-BASED STAFF SUPPORTED CRITICAL WORK IN NEIGHBORING COUNTRIES, INCLUDING BANGLADESH, MYANMAR, NEPAL, AND VIETNAM. PATH'S RICE FORTIFICATION TEAM IN INDIA SUPPORTED MYANMAR TO LAUNCH ITS RICE FORTIFICATION PROGRAM THROUGH OPEN MARKET CHANNELS. FINALLY, THE DEPARTMENT OF DRUG ADMINISTRATION OF NEPAL ENTRUSTED PATH TO CONDUCT TRAINING FOR THE NATIONAL PHARMACOVIGILANCE PROGRAM. IN VIETNAM, PATH PROVIDES TECHNICAL ASSISTANCE THAT ENABLES THIS QUICKLY DEVELOPING COUNTRY TO ADAPT TO AND ADDRESS UNIQUE HEALTH CHALLENGES ARISING FROM RAPID GROWTH. IN 2016, PATH CONTINUED TO SUPPORT IMPROVEMENT OF PANDEMIC PREPAREDNESS BY HELPING THE COUNTRY TO PRODUCE ITS OWN INFLUENZA VACCINE SUPPLY. WITH SUPPORT FROM PATH, THE INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS SUCCESSFULLY COMPLETED A PHASE 1 CLINICAL TRIAL OF A SEASONAL INFLUENZA VACCINE WHICH TARGETS THREE STRAINS OF INFLUENZA. HAND IN HAND WITH THIS EFFORT, PATH'S GLOBAL HEALTH SECURITY PARTNERSHIP WITH THE CDC PROVIDES TECHNICAL ASSISTANCE TO THE MOH TO IMPROVE INFECTIOUS DISEASE SURVEILLANCE SYSTEMS THROUGH BETTER DATA USE AND MANAGEMENT, REAL-TIME SURVEILLANCE, REPORTING, AND DEVELOPMENT OF EMERGENCY OPERATIONS CENTERS. VIETNAMESE LEADERS OPENED THE FIRST EMERGENCY OPERATION CENTER, IN HANOI, IN 2016. PATH ALSO CONTINUES TO SUPPORT VIETNAM TO ELIMINATE PERSISTENT INFECTIOUS DISEASES, INCLUDING HIV AND TB. THIS YEAR, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID)/PATH HEALTHY MARKETS PROJECT CONTINUED TO LEAD INNOVATIVE EFFORTS TO SUPPORT VIETNAM TO REACH GLOBAL HIV PREVENTION GOALS TOWARD ELIMINATING HIV BY 2030 (THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS "90-90-90" TARGETS). IN COLLABORATION WITH THE MOH, HEALTHY MARKETS LAUNCHED HIV LAY-TESTING (IN LATE 2015) AND SELF-TESTING (IN MAY 2016) AS A WAY TO INCREASE HIV TESTING OPTIONS AND ACCESS FOR THOSE MOST AT RISK OF INFECTION. HIV SERVICES AND PRODUCTS WERE WIDELY PROMOTED THROUGH HEALTHY MARKETS' TRAILBLAZING LGBT FACEBOOK COMMUNITY, RAINBOW VILLAGE, WHICH HAD ALMOST 200,000 FOLLOWERS BY THE END OF 2016. NONTRADITIONAL STRATEGIC PARTNERSHIPS INCLUDED MTV VIETNAM AND THE POPULAR GAY SOCIAL NETWORKING SITE GRINDR. BUILDING ON OUR LONGSTANDING EFFORTS TO TACKLE TB IN VIETNAM, IN 2016 PATH LAUNCHED THE BREATH FOR LIFE PROJECT TO ADDRESS PEDIATRIC TB. AN ESTIMATED 90 PERCENT OF PEDIATRIC TB CASES GO UNDETECTED IN VIETNAM EVERY YEAR. PATH ALSO LAUNCHED A FLAGSHIP NCD PROJECT IN VIETNAM. THE COMMUNITIES FOR HEALTHY HEARTS PROJECT AIMS TO DEVELOP A MODEL THAT PROMOTES AWARENESS OF, ACCESS TO, AND QUALITY OF HYPERTENSION SERVICES FOR LOW-INCOME HOUSEHOLDS IN HO CHI MINH CITY.IN ZAMBIA, PATH CONTINUED TO PARTNER WITH THE GOVERNMENT, HEALTH WORKERS, COMMUNITIES, AND OTHERS TO TACKLE KEY HEALTH PRIORITIES. ZAMBIA HAS MADE A BOLD COMMITMENT TO ELIMINATE MALARIA BY 2021. IN 2016, PATH SUPPORTED THE GOVERNMENT TO DEVELOP A NEW NATIONAL STRATEGIC PLAN FOR MALARIA ELIMINATION USING EXISTING AND NEW TOOLS AND INTERVENTIONS. THROUGH MACEPA, PATH SUPPORTED THE EXPANSION OF MALARIA SURVEILLANCE AND TREATMENT SERVICES AT THE COMMUNITY LEVEL IN MANY AREAS OF THE COUNTRY'S SOUTHERN AND WESTERN PROVINCES. THIS WORK WAS SUPPLEMENTED BY PRIVATE-SECTOR ENGAGEMENT IN DATA ANALYSIS, VISUALIZATION, AND COMMUNICATION AT MANY LEVELS, FROM COMMUNITY TO NATIONAL.TO HELP TAKE TRANSMISSION TO ZERO, PATH SUPPORTED THE DEVELOPMENT AND FIELD-TESTING OF MORE SENSITIVE DIAGNOSTIC TOOLS THAT CAN DETECT LOW-DENSITY MALARIA INFECTIONS THAT MAY SPREAD DISEASE EVEN THOUGH THEY DO NOT CAUSE SYMPTOMS. PATH ALSO SUPPORTED THE APPLICATION OF RESEARCH FINDINGS TO THE SUCCESSFUL IMPLEMENTATION OF MASS DRUG ADMINISTRATION; THERE IS NOW ROUTINE PROGRAM USE OF MASS DRUG ADMINISTRATION BY DISTRICT HEALTH TEAMS AT THE LOCAL LEVEL. LEADERS REVISED THE NEW NATIONAL STRATEGY TO INCLUDE AN APPROACH TO MALARIA THAT COMBINES EVIDENCE ON NEW TOOLS AND INTERVENTIONS WITH EXISTING STRATEGIES. THIS HELPED REALIGN FUNDING PRIORITIES TO ACHIEVE ELIMINATION.AS PART OF OUR LEADERSHIP OF THE MALARIACARE PARTNERSHIP, PATH TRAINED AND SUPPORTED LABORATORY TECHNICIANS AND CLINICIANS IN ZAMBIA TO ACCURATELY DIAGNOSE MALARIA AND WORK WITH PATIENTS TO MANAGE THE DISEASE. THIS WILL HELP THE GOVERNMENT MOVE TOWARD ITS GOAL OF ENSURING THAT EVERY PATIENT WITH MALARIA SYMPTOMS IS TESTED, THAT TESTING IS OF HIGH QUALITY, AND THAT EVERY PATIENT RECEIVES PROPER TREATMENT.IN PARTS OF ZAMBIA WHERE MALARIA RATES ARE STILL HIGH, WE ARE LEADING A NEWER PROJECT CALLED THE PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO). PAMO IS APPLYING LESSONS LEARNED DURING THE PAST DECADE TO ACCELERATE MALARIA REDUCTION IN FOUR PROVINCES WITH HIGH RATES OF DISEASE TRANSMISSION.PATH HAS ALSO BEEN WORKING WITH THE MOH AND OTHER PARTNERS TO CREATE AND DEPLOY A POWERFUL SYSTEM TO HELP HEALTH FACILITIES MONITOR THEIR SUPPLY AND USE OF CRUCIAL HEALTH COMMODITIES (MEDICINES, INJECTION DEVICES, AND VACCINES) TO ENSURE THEY ARE AVAILABLE WHEN AND WHERE NEEDED. THE THRIVE PROJECT CONTINUED TO WORK IN FOUR PROVINCES AND 50 FACILITIES TO IMPROVE NUTRITION, ESPECIALLY FOR PEOPLE LIVING WITH HIV, PREGNANT WOMEN, AND ORPHANS AND VULNERABLE CHILDREN. THROUGH THE FAMILY HEALTH PROJECT, PATH WORKS CLOSELY WITH GOVERNMENT AND ADVOCACY PARTNERS IN ZAMBIA TO ENSURE THAT MATERNAL AND NEWBORN HEALTH ARE HIGH PRIORITIES IN NATIONAL POLICY AND BUDGETING. IN 2016, WE SUPPORTED THE GOVERNMENT TO ENACT A NATIONAL NEWBORN HEALTH FRAMEWORK TO IDENTIFY HIGH-PRIORITY INTERVENTIONS AND ACTIVITIES FOR SCALE-UP.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$36,420,596	ExpenseAmt
Grant	$7,702,857	GrantAmt
Revenue	$24,100	RevenueAmt
Desc	ADVOCACY AND PUBLIC POLICY:PATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, WITH MULTILATERAL HEALTH LEADERS ENGAGED IN GLOBAL POLICY AND PLANNING, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2016, PATH LED ADVOCACY EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES AND EUROPE FOR RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, AND IMMUNIZATION. ONE EXAMPLE OF OUR SUCCESS WAS WHO'S LISTING OF OXYGEN IN ITS GLOBAL MODEL LIST OF ESSENTIAL MEDICINES (EML) AND EML FOR CHILDREN. WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS THIS YEAR, THE GOVERNMENT IN THE DRC AGREED TO RELEASE VITAL IMMUNIZATION FUNDS. THIS PREVENTED THE COUNTRY FROM DEFAULTING ON A CO-FINANCING COMMITMENT IT HAD MADE TO GAVI, THE VACCINE ALLIANCE. IN KENYA, THE GOVERNMENT REVISED ITS ESSENTIAL MEDICINES LIST TO INCLUDE A NEW TYPE OF INJECTABLE CONTRACEPTIVE, A KEY STEP TO EXPANDING ACCESS TO FAMILY PLANNING FOR WOMEN IN HARD-TO-REACH POPULATIONS.MARKET DYNAMICS:PATH'S MARKET DYNAMICS PROGRAM ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT. IT BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION, ALIGNS EXPERTISE ACROSS TEAMS, AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. IN 2016, OUR WORK FOCUSED ON ASSESSING MARKETS AND IMPROVING MARKET FUNCTIONING FOR MALARIA DRUGS AND DRUG INTERMEDIATES, MALARIA DIAGNOSTICS, OXYGEN THERAPY DEVICES, DEVICES FOR TREATMENT OF PRECANCEROUS CERVICAL LESIONS, AND DEVICES FOR WATER TREATMENT. THE MARKET DYNAMICS PROGRAM ALSO COLLABORATED WITH THE ADVOCACY AND PUBLIC POLICY DEPARTMENT TO STRENGTHEN MARKETS FOR MATERNAL AND NEWBORN HEALTH PRODUCTS THROUGH POLICY ADVOCACY. TECHNOLOGY DEVELOPMENT AND INTRODUCTION:IN 2016, THE PRODUCT DEVELOPMENT DEPARTMENT AT PATH WAS RESTRUCTURED INTO TWO DIVISIONS: PATH ESSENTIAL MEDICINES, COMPRISING OUR VACCINE AND DRUG WORK, INCLUDING CVIA; AND PATH TECHNOLOGY DEVELOPMENT AND INTRODUCTION (TDI), COMPRISING OUR DEVICES AND TOOLS AND DIAGNOSTICS WORK AND STRONG ENGAGEMENT WITH KEY COUNTRY PROGRAMS TO SUPPORT LOCAL INNOVATION.TDI IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT DIAGNOSTICS, DEVICES, AND TOOLS THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. IT IS ORGANIZED AS A NETWORK OF PATH "IMPACT LABS" WITH FUNCTIONAL EXPERTISE AND RELATIONSHIPS WITH DONORS, ENTREPRENEURS, HEALTH CARE PROVIDERS, ACADEMIA, RESEARCH INSTITUTES, AND POLICYMAKERS IN CHINA, INDIA, SOUTH AFRICA, AND THE UNITED STATES.THE DEVICES AND TOOLS PROGRAM (UNDER THE NEW TDI) IS PATH'S INNOVATIVE TECHNOLOGY ARM. THE GROUP WORKS WITH PARTNERS AND INNOVATORS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH AND LIVES OF FAMILIES LIVING IN LMIC.IN 2016, THE DEVICES AND TOOLS PROGRAM COMPLETED THE TECHNOLOGIES FOR HEALTH PROGRAM (HEALTHTECH), A FIVE-YEAR COLLABORATION WITH USAID TO DEVELOP AND INTRODUCE LOW-COST HEALTH TOOLS TO ACCELERATE REDUCTIONS IN INFECTIOUS DISEASES AS WELL AS MORTALITY AND MORBIDITY IN MATERNAL AND CHILD HEALTH. A TOTAL OF 93 RESEARCH/DEVELOPMENT PARTNERSHIPS WERE FORMALIZED DURING THE HEALTHTECH PROJECT; 25 HIGH-POTENTIAL TECHNOLOGIES WERE IDENTIFIED; 9 TECHNOLOGIES WERE DESIGNED WITH IN-COUNTRY USER INPUT; AND 7 TECHNOLOGIES WERE EVALUATED AND INTRODUCED IN THE FIELD-SUCH AS THE SILCS DIAPHRAGM, MARKETED IN MORE THAN 25 COUNTRIES. THE DEVICES AND TOOLS PROGRAM ALSO DEVELOPED AND ADVANCED VACCINE INNOVATIONS TO IMPROVE THE ADMINISTRATION OF VACCINES IN THREE AREAS: DELIVERY, COLD CHAIN, AND FORMULATION. PROJECT MILESTONES INCLUDED THE COMPLETION OF AN INACTIVATED POLIOVIRUS VACCINE FREEZE SENSITIVITY STUDY. STAFF PRODUCED JOURNAL ARTICLES AND REPORTS ON OUR RESEARCH FINDINGS, RANGING FROM INTRADERMAL DELIVERY OF A FRACTIONAL DOSE OF INACTIVATED POLIOVIRUS VACCINE, TO FAST-DISSOLVING TABLETS FOR ANTIRETROVIRAL THERAPY FOR CHILDREN, TO ROOT CAUSES OF COLD CHAIN EQUIPMENT FAILURE IN UGANDA. PATH'S WORK TO DEVELOP AND INTRODUCE FAST, ACCURATE DIAGNOSTIC TECHNOLOGIES INCLUDES TOOLS TO DETECT AND MONITOR NTDS, MALARIA, POLIO, AND NCDS.IN A KEY 2016 MILESTONE, PATH AND A PRIVATE-SECTOR PARTNER LAUNCHED TWO RAPID TESTS FOR NTDS. THE FIRST IS A DUAL-DETECTION (OR 'BIPLEX') TEST THAT CAN QUICKLY DETECT PREVIOUS EXPOSURE TO THE ONCHOCERCIASIS PARASITE, WHICH CAUSES RIVER BLINDNESS, AND LYMPHATIC FILARIASIS (LF), A DISABLING AND DISFIGURING DISEASE. PATH AND OUR PARTNER ALSO LAUNCHED A MONOPLEX RAPID DETECTION TEST FOR LF. BOTH TESTS ARE AVAILABLE TO SUPPORT SURVEILLANCE ACTIVITIES FOR ONCHOCERCIASIS AND LF ELIMINATION PROGRAMS.OUR PIONEERING WORK ON THE USE OF DIAGNOSTICS FOR MALARIA ELIMINATION INCLUDED DEVELOPING NEW OPTIONS TO IMPROVE DETECTION OF THE MALARIA PARASITE AND TESTS TO GUIDE CLINICAL CARE OF PATIENTS. WITH OUR DEVELOPMENT PARTNERS, PATH ADVANCED SEVERAL NEW PROTOTYPES FOR RAPID TESTS FOR G6PD DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. WE ALSO WORKED WITH A PUBLIC-SECTOR PARTNER TO ADVANCE A NEW, HIGHLY SENSITIVE TEST THAT CAN DETECT LOW LEVELS OF MALARIA INFECTION THAT MIGHT OTHERWISE BE MISSED IN ASYMPTOMATIC PATIENTS.WITH ANOTHER PRIVATE-SECTOR PARTNER, PATH ADVANCED A TOOL FOR POPULATION-BASED SURVEILLANCE OF MICRONUTRIENT DEFICIENCIES. THIS TEST, WHICH DETECTS UP TO SEVEN NUTRITION- AND DISEASE-RELATED BIOMARKERS IN A SINGLE SAMPLE OF HUMAN SERUM, ADDRESSES THE NEED FOR TOOLS THAT CAN ACCURATELY AND RAPIDLY ASSESS NUTRITIONAL DEFICIENCIES AT A LARGE SCALE.FURTHER, AS PART OF THE GLOBAL EFFORT TO ERADICATE POLIO, PATH AND OUR PARTNERS CONDUCTED STUDIES IN KENYA AND PAKISTAN TO VALIDATE A NEW TOOL TO DETECT POLIOVIRUS IN WASTEWATER AND SEWAGE.TO ACCELERATE THE MOST PROMISING HEALTH TECHNOLOGIES, PATH HAS ESTABLISHED A NETWORK OF IMPACT LABS IN CHINA (BEIJING), INDIA (NEW DELHI), SOUTH AFRICA (CAPE TOWN), AND THE UNITED STATES (SEATTLE). THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS ALL FOCUSED ON INNOVATIVE PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. THROUGH THE NETWORK OF IMPACT LABS, PATH CAN LEVERAGE WORLD-CLASS GLOBAL AND COUNTRY EXPERTISE WHEN SUPPORTING PARTNERS TO ACCELERATE THE DEVELOPMENT AND INTRODUCTION OF SCALABLE DEVICES, TOOLS, AND DIAGNOSTICS FOR HEALTH.SPECIAL INITIATIVES:PATH IS ENGAGED IN A VARIETY OF PROJECTS THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. PATH LAUNCHED ITS FIRST TWO HEALTH IMPACT TEAMS IN 2014, FOCUSED ON MALARIA AND HIV/AIDS. AS OF 2016, WE HAVE ACTIVE OR PLANNED HEALTH IMPACT TEAMS IN FIVE ADDITIONAL HEALTH AREAS: MATERNAL AND NEWBORN HEALTH, NUTRITION INNOVATION, SRH, GLOBAL HEALTH SECURITY, AND HEALTH SYSTEMS STRENGTHENING. EACH TEAM GOES THROUGH A STAGED PROCESS OF SCALE-UP AND GROWTH. ULTIMATELY, THESE TEAMS ARE CHARGED WITH DEVELOPING AND EVOLVING STRATEGY, PURSUING NEW OPPORTUNITIES, DELIVERING HIGH-QUALITY RESULTS, STRENGTHENING AND CONNECTING PATH TALENT ACROSS GEOGRAPHIES AND PROGRAMS RELATED TO AN AREA, AND POSITIONING PATH EXTERNALLY TO COLLABORATE AND ADVOCATE.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$36,420,596	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$7,702,857	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$24,100	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$242,619,077	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Temp Or Permanent Endowments	Yes (1)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	0	ReportOtherLiabilitiesInd
Include FIN48 Footnote	0	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	0	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (1)	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	Yes (1)	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	Yes (1)	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	Yes (1)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (1)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	Yes (1)	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
Info In Schedule O Part V	Yes (X)	InfoInScheduleOPartVInd
IRP Document	270	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	783	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (1)	ForeignFinancialAccountInd
Foreign Country	BE	ForeignCountryCd
Foreign Country	CH	ForeignCountryCd
Foreign Country	CG	ForeignCountryCd
Foreign Country	ET	ForeignCountryCd
Foreign Country	GH	ForeignCountryCd
Foreign Country	IN	ForeignCountryCd
Foreign Country	KE	ForeignCountryCd
Foreign Country	MI	ForeignCountryCd
Foreign Country	MZ	ForeignCountryCd
Foreign Country	OC	ForeignCountryCd
Foreign Country	PE	ForeignCountryCd
Foreign Country	SG	ForeignCountryCd
Foreign Country	SF	ForeignCountryCd
Foreign Country	SZ	ForeignCountryCd
Foreign Country	TZ	ForeignCountryCd
Foreign Country	UG	ForeignCountryCd
Foreign Country	UK	ForeignCountryCd
Foreign Country	UP	ForeignCountryCd
Foreign Country	VM	ForeignCountryCd
Foreign Country	ZA	ForeignCountryCd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	16	GoverningBodyVotingMembersCnt
Independent Voting Member	15	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	OLIVIA POLIUS CHIEF FINANCIAL OFFICER	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	2062853500	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	2201 WESTLAKE AVE SUITE 200	AddressLine1Txt
City	SEATTLE	CityNm
State Abbreviation	WA	StateAbbreviationCd
ZIP	98121	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
DEAN ALLEN
CHAIR	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
GEORGE GOTSADZE
VICE CHAIR (UNTIL 06/2016)	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
FELIX OLALE
SECRETARY	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
DAVID KING
TREASURER	2.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
JO ADDY
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
PHYLLIS CAMPBELL
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
ALEX CHIKA EZEH
DIRECTOR (UNTIL 06/2016)	2.00	0.00	Yes (X)		$0	$0	$0
RAJENDRA VATTIKUTI
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
KEVIN REILLY
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
TSITSI MASIYIWA
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
IREENA VITTAL
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
YEHONG ZHANG
DIRECTOR	2.00	0.00	Yes (X)		$0	$0	$0
LAURIE MICHAELS
DIRECTOR (BEGAN 03/2016)	2.00	0.00	Yes (X)		$0	$0	$0
PEGGY JOHNSON
DIRECTOR (BEGAN 12/2016)	2.00	0.00	Yes (X)		$0	$0	$0
GARY LOCKE
DIRECTOR (BEGAN 06/2016)	2.00	0.00	Yes (X)		$0	$0	$0
BRUCE MCNAMER
DIRECTOR (BEGAN 06/2016)	2.00	0.00	Yes (X)		$0	$0	$0
DEANNA OPPENHEIMER
DIRECTOR (BEGAN 12/2016)	2.00	0.00	Yes (X)		$0	$0	$0
DENNIS SCHMATZ
DIRECTOR (BEGAN 06/2016)	2.00	0.00	Yes (X)		$0	$0	$0
PETER SMITH
DIRECTOR (06/2016-12/2016)	2.00	0.00	Yes (X)		$0	$0	$0
STEPHEN B DAVIS
PRESIDENT AND CEO	38.00	2.00		Yes (X)	$623,273	$0	$62,041
OLIVIA D POLIUS
CHIEF FINANCIAL OFFICER	38.00	2.00		Yes (X)	$303,385	$0	$48,805
DANIEL LASTER
COO AND GENERAL COUNSEL	38.00	2.00		Yes (X)	$304,582	$0	$42,894
DAVID C KASLOW
VP - PRODUCT DEVELOPMENT	38.00	2.00			$354,854	$0	$63,492	Yes (X)
AMIE E BATSON
CHIEF STRATEGY OFFICER	39.00	1.00			$293,566	$0	$26,850	Yes (X)
KATHY CAHILL
VP - INTERNATIONAL DEVELOPMENT	40.00	0.00			$272,175	$0	$36,605	Yes (X)
DAVID W FLEMING
VP - PUBLIC HEALTH	40.00	0.00			$267,868	$0	$47,992	Yes (X)
KATHRYN A O'DRISCOLL
CHIEF HUMAN RESOURCES OFFICER	40.00	0.00			$237,269	$0	$43,559	Yes (X)
MARK D MURRAY
VP - GLOBAL ENGAGEMENT	40.00	0.00			$253,331	$0	$55,597	Yes (X)
JOHN SKIBIAK
ASSOCIATE DIRECTOR	40.00	0.00			$449,670	$0	$71,527		Yes (X)
JAMES B MCKENNA
ASSOCIATE DIRECTOR	40.00	0.00			$375,756	$0	$59,808		Yes (X)
TRAD M HATTON
CHIEF OF PARTY	40.00	0.00			$314,245	$0	$39,211		Yes (X)
RIKKA E TRANGSRUD
COUNTRY PROGRAM LEADER	40.00	0.00			$292,872	$0	$35,718		Yes (X)
DAVID A SHOULTZ
GLOBAL PROGRAM LEADER	40.00	0.00			$283,428	$0	$56,773		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,626,274	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$690,872	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	285	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
WIDENET CONSULTING GROUP LLC
11400 SE 6TH ST 130	BELLEVUE	WA	98004	CONSULTING	$1,263,147
TARGET CW
9475 CHESAPEAKE DRIVE	SAN DIEGO	CA	92123	GENERAL CONTRACTOR	$530,652
SLALOM LLC
821 2ND AVE 1900	SEATTLE	WA	98124	CONSULTING	$496,257
AEROTEK INC
7301 PARKWAY DRIVE S	HANOVER	MD	21076	STAFFING SERVICES	$310,568
NORTHERN TRUST
50 S LASALLE ST	CHICAGO	IL	60675	ASSET MANAGEMENT	$295,241

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	32	CntrctRcvdGreaterThan100KCnt
Related Organizations	$19,363,854	RelatedOrganizationsAmt
Government Grants	$128,353,466	GovernmentGrantsAmt
All Other Contributions	$150,598,668	AllOtherContributionsAmt
Noncash Contributions	$1,158,273	NoncashContributionsAmt
Total Contributions	$298,315,988	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (2 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt
HONORARIUM	900099	$26,250	$26,250
SALES	900099	$3,215	$3,215

Field	Value	IRS element (for citing)
Total Program Service Revenue	$29,465	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,797,794	TotalRevenueColumnAmt
Exclusion	$1,797,794	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$59,787,840	SecuritiesAmt
Other	$45,000	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$59,762,566	SecuritiesAmt
Other	$125,576	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$25,274	SecuritiesAmt
Other	-$80,576	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$55,302	TotalRevenueColumnAmt
Exclusion	-$55,302	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	ExclusionExclusionAmt
GAIN-FOREIGN EXCH.	900099	$4,330,195	$4,330,195
REIMBURSEMENTS	900099	$174,639	$174,639
OTHER	900099	$163,559	$163,559

Field	Value	IRS element (for citing)
Other Revenue Total	$4,668,393	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$304,756,338	TotalRevenueColumnAmt
Related Or Exempt Func Income	$29,465	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$6,410,885	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$30,538,380	TotalAmt
Program Services	$30,538,380	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$29,000	TotalAmt
Program Services	$29,000	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$36,572,138	TotalAmt
Program Services	$36,572,138	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$3,338,138	TotalAmt
Program Services	$917,083	ProgramServicesAmt
Management And General	$2,343,772	ManagementAndGeneralAmt
Fundraising	$77,283	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$90,959,712	TotalAmt
Program Services	$54,707,206	ProgramServicesAmt
Management And General	$34,725,934	ManagementAndGeneralAmt
Fundraising	$1,526,572	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$9,104,500	TotalAmt
Management And General	$9,104,500	ManagementAndGeneralAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$12,846,115	TotalAmt
Program Services	$848,514	ProgramServicesAmt
Management And General	$11,997,601	ManagementAndGeneralAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$6,480,037	TotalAmt
Program Services	$458,381	ProgramServicesAmt
Management And General	$6,021,656	ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$536,989	TotalAmt
Program Services	$295,764	ProgramServicesAmt
Management And General	$241,170	ManagementAndGeneralAmt
Fundraising	$55	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$502,506	TotalAmt
Program Services	$65,678	ProgramServicesAmt
Management And General	$436,828	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$45,041	TotalAmt
Program Services	$21,000	ProgramServicesAmt
Management And General	$24,041	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$295,241	TotalAmt
Management And General	$295,241	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$16,394,283	TotalAmt
Program Services	$11,420,324	ProgramServicesAmt
Management And General	$4,856,181	ManagementAndGeneralAmt
Fundraising	$117,778	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$377,868	TotalAmt
Program Services	$237,973	ProgramServicesAmt
Management And General	$95,492	ManagementAndGeneralAmt
Fundraising	$44,403	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$5,996,638	TotalAmt
Program Services	$4,795,807	ProgramServicesAmt
Management And General	$1,119,412	ManagementAndGeneralAmt
Fundraising	$81,419	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,184,901	TotalAmt
Program Services	$265,468	ProgramServicesAmt
Management And General	$867,086	ManagementAndGeneralAmt
Fundraising	$52,347	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$70,856	TotalAmt
Program Services	$70,856	ProgramServicesAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$10,989,044	TotalAmt
Program Services	$213,218	ProgramServicesAmt
Management And General	$10,775,826	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$22,206,798	TotalAmt
Program Services	$19,432,713	ProgramServicesAmt
Management And General	$2,682,213	ManagementAndGeneralAmt
Fundraising	$91,872	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$10,664,330	TotalAmt
Program Services	$9,651,771	ProgramServicesAmt
Management And General	$658,934	ManagementAndGeneralAmt
Fundraising	$353,625	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$41,156	TotalAmt
Management And General	$41,156	ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$3,109,950	TotalAmt
Management And General	$3,109,950	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$428,986	TotalAmt
Program Services	$53,240	ProgramServicesAmt
Management And General	$375,746	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
SUBCONTRACTS	$20,893,797	$18,858,698	$1,608,175	$426,924
EQUIP RENT & MAINT	$5,660,882	$5,120,434	$510,907	$29,541
FACILITIES ALLOC	$0	$11,302,017	-$11,724,902	$422,885
LEAVE & BENS ALLOC	$0	$28,978,004	-$29,828,131	$850,127

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$16,752,884	TotalAmt
Program Services	$7,765,410	ProgramServicesAmt
Management And General	$8,923,574	ManagementAndGeneralAmt
Fundraising	$63,900	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$306,020,170	TotalAmt
Program Services	$242,619,077	ProgramServicesAmt
Management And General	$59,262,362	ManagementAndGeneralAmt
Fundraising	$4,138,731	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$17,233,932	BOYAmt
EOY	$101,995,891	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$70,140,432	BOYAmt
EOY	$1,334,550	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$213,160,918	BOYAmt
EOY	$213,222,701	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$8,998,343	BOYAmt
EOY	$7,385,621	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$8,519,638	BOYAmt
EOY	$6,129,231	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$34,897,333	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$21,670,106	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$15,205,982	BOYAmt
EOY	$13,227,227	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$125,477,380	BOYAmt
EOY	$107,031,338	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
EOY	$439,232	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$174,495	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$458,736,625	BOYAmt
EOY	$450,940,286	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$44,777,022	BOYAmt
EOY	$52,167,762	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$2,467,142	BOYAmt
EOY	$1,525,153	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$47,244,164	BOYAmt
EOY	$53,692,915	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$20,834,939	BOYAmt
EOY	$25,545,902	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$387,267,912	BOYAmt
EOY	$368,307,703	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$3,389,610	BOYAmt
EOY	$3,393,766	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$411,492,461	BOYAmt
EOY	$397,247,371	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$458,736,625	BOYAmt
EOY	$450,940,286	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$1,263,832	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$769,847	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	-$13,751,105	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$171,536,869	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$260,656,932	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$286,891,535	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$243,499,792	CurrentTaxYearMinus1YearAmt
Current Tax Year	$298,315,988	CurrentTaxYearAmt
Total	$1,260,901,116	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$171,536,869	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$260,656,932	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$286,891,535	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$243,499,792	CurrentTaxYearMinus1YearAmt
Current Tax Year	$298,315,988	CurrentTaxYearAmt
Total	$1,260,901,116	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$455,077,614	SubstantialContributorsTotAmt
Public Support Total170	$805,823,502	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$2,295,453	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,577,831	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,370,599	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,471,233	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,797,794	CurrentTaxYearAmt
Total	$8,512,910	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus2 Years	$38,502	CurrentTaxYearMinus2YearsAmt
Total	$38,502	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$730,742	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,432,891	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$763,131	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$2,551,502	CurrentTaxYearMinus1YearAmt
Current Tax Year	$4,668,393	CurrentTaxYearAmt
Total	$11,146,659	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$1,280,599,187	TotalSupportAmt
Gross Receipts Rltd Activities	$238,486	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.62930	PublicSupportCY170Pct
Public Support PY170	0.65000	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$470	FilingOrganizationsTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$168,521	FilingOrganizationsTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$168,991	FilingOrganizationsTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$305,851,179	FilingOrganizationsTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$306,020,170	FilingOrganizationsTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$106,680	CurrentYearMinus3Amt
Current Year Minus2	$222,686	CurrentYearMinus2Amt
Current Year Minus1	$156,961	CurrentYearMinus1Amt
Current Year	$168,991	CurrentYearAmt
Total	$655,318	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$3,098	CurrentYearMinus3Amt
Current Year Minus2	$1,207	CurrentYearMinus2Amt
Current Year Minus1	$14,461	CurrentYearMinus1Amt
Current Year	$470	CurrentYearAmt
Total	$19,236	TotalAmt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$8,897,224	BeginningYearBalanceAmt
Contributions	$4,256	ContributionsAmt
Investment Earnings Or Losses	$907,978	InvestmentEarningsOrLossesAmt
Other Expenditures	$470,209	OtherExpendituresAmt
End Year Balance	$9,339,249	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,404,188	BeginningYearBalanceAmt
Contributions	$2,665	ContributionsAmt
Investment Earnings Or Losses	-$58,783	InvestmentEarningsOrLossesAmt
Other Expenditures	$450,846	OtherExpendituresAmt
End Year Balance	$8,897,224	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,016,994	BeginningYearBalanceAmt
Contributions	$9,350	ContributionsAmt
Investment Earnings Or Losses	$768,184	InvestmentEarningsOrLossesAmt
Other Expenditures	$390,340	OtherExpendituresAmt
End Year Balance	$9,404,188	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$7,806,786	BeginningYearBalanceAmt
Contributions	$2,550	ContributionsAmt
Investment Earnings Or Losses	$1,503,301	InvestmentEarningsOrLossesAmt
Other Expenditures	$295,643	OtherExpendituresAmt
End Year Balance	$9,016,994	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,868,767	BeginningYearBalanceAmt
Contributions	$5,392	ContributionsAmt
Investment Earnings Or Losses	$932,627	InvestmentEarningsOrLossesAmt
End Year Balance	$7,806,786	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.36000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.36000	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.28000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$20,335,505	OtherCostOrOtherBasisAmt
Depreciation	$10,320,252	DepreciationAmt
Book Value	$10,015,253	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$10,972,612	OtherCostOrOtherBasisAmt
Depreciation	$8,927,999	DepreciationAmt
Book Value	$2,044,613	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$3,589,216	OtherCostOrOtherBasisAmt
Depreciation	$2,421,855	DepreciationAmt
Book Value	$1,167,361	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$13,227,227	TotalBookValueLandBuildingsAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART V, LINE 4:	FormAndLineReferenceDesc
Explanation	PATH UTILIZES THE INCOME EARNED ON THE ENDOWMENT FUNDS AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY.	ExplanationTxt

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (53 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Region Total ExpendituresRegionTotalExpendituresAmt	Specific Services ProvidedSpecificServicesProvidedTxt
CENTRAL AMERICA AND THE CARIBBEAN	0	0	MANAGEMENT & GENERAL	$382
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	$21,212	ESSENTIAL MEDICINE
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	$34,953	PUBLIC HEALTH
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	$784	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	$978	OTHER
CENTRAL AMERICA AND THE CARIBBEAN	0	0	GRANTMAKING	$677,302
EAST ASIA AND THE PACIFIC	4	76	MANAGEMENT & GENERAL	$1,949,652
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	$847,207	ESSENTIAL MEDICINE
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	$2,972,452	INTERNATIONAL DEVELOPMENT
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	$311,712	PUBLIC HEALTH
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	$20,720	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	$15,708	OTHER
EAST ASIA AND THE PACIFIC	0	0	FUNDRAISING	$3,094
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING	$2,948,493
EUROPE	2	24	MANAGEMENT & GENERAL	$291,161
EUROPE	0	0	PROGRAM SERVICES	$3,158,742	ESSENTIAL MEDICINE
EUROPE	0	0	PROGRAM SERVICES	$64,074	INTERNATIONAL DEVELOPMENT
EUROPE	0	0	PROGRAM SERVICES	$3,913,766	PUBLIC HEALTH
EUROPE	0	0	PROGRAM SERVICES	$46,794	OTHER
EUROPE	0	0	FUNDRAISING	$250,755
EUROPE	0	0	GRANTMAKING	$17,747,800
MIDDLE EAST AND NORTH AFRICA	0	0	PROGRAM SERVICES	$4,530	ESSENTIAL MEDICINE
MIDDLE EAST AND NORTH AFRICA	0	0	PROGRAM SERVICES	$8,297	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
NORTH AMERICA	0	0	MANAGEMENT & GENERAL	$3,049
NORTH AMERICA	0	0	PROGRAM SERVICES	$18,888	ESSENTIAL MEDICINE
NORTH AMERICA	0	0	PROGRAM SERVICES	$74,273	PUBLIC HEALTH
NORTH AMERICA	0	0	PROGRAM SERVICES	$650	OTHER
NORTH AMERICA	0	0	FUNDRAISING	$6,571
NORTH AMERICA	0	0	GRANTMAKING	$479,798
RUSSIA AND NEIGHBORING STATES	1	15	MANAGEMENT & GENERAL	$590,046
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	$520,576	INTERNATIONAL DEVELOPMENT
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	$562,153	PUBLIC HEALTH
RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	$32,984	OTHER
RUSSIA AND NEIGHBORING STATES	0	0	GRANTMAKING	$106,455
SOUTH AMERICA	1	3	MANAGEMENT & GENERAL	$105,003
SOUTH AMERICA	0	0	PROGRAM SERVICES	$1,070	ESSENTIAL MEDICINE
SOUTH AMERICA	0	0	PROGRAM SERVICES	$207,048	PUBLIC HEALTH
SOUTH AMERICA	0	0	GRANTMAKING	$74,559
SOUTH ASIA	3	59	MANAGEMENT & GENERAL	$2,020,370
SOUTH ASIA	0	0	PROGRAM SERVICES	$467,233	ESSENTIAL MEDICINE
SOUTH ASIA	0	0	PROGRAM SERVICES	$1,449,874	INTERNATIONAL DEVELOPMENT
SOUTH ASIA	0	0	PROGRAM SERVICES	$1,011,072	PUBLIC HEALTH
SOUTH ASIA	0	0	PROGRAM SERVICES	$74,755	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
SOUTH ASIA	0	0	PROGRAM SERVICES	$48,420	OTHER
SOUTH ASIA	0	0	GRANTMAKING	$4,474,672
SUB-SAHARAN AFRICA	25	662	MANAGEMENT & GENERAL	$13,942,909
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	$1,612,848	ESSENTIAL MEDICINE
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	$20,607,949	INTERNATIONAL DEVELOPMENT
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	$27,884,386	PUBLIC HEALTH
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	$87,031	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	$1,500,972	OTHER
SUB-SAHARAN AFRICA	0	0	FUNDRAISING	$6,011
SUB-SAHARAN AFRICA	0	0	GRANTMAKING	$10,063,059

Field	Value	IRS element (for citing)
Subtotal Offices	4	SubtotalOfficesCnt
Subtotal Employees	76	SubtotalEmployeesCnt
Continutation Total Office	32	ContinutationTotalOfficeCnt
Continutation Total Employee	763	ContinutationTotalEmployeeCnt
Total Office	36	TotalOfficeCnt
Total Employee	839	TotalEmployeeCnt
Subtotal Spent	$3,532,470	SubtotalSpentAmt
Continuation Spent	$119,792,782	ContinuationSpentAmt
Total Spent	$123,325,252	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (262 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
CENTRAL AMERICA AND THE CARIBBEAN	PUBLIC HEALTH	$234,907	CHECK/WIRE
CENTRAL AMERICA AND THE CARIBBEAN	PUBLIC HEALTH	$212,545	CHECK/WIRE
CENTRAL AMERICA AND THE CARIBBEAN	PUBLIC HEALTH	$229,850	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$285,600	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$1,183,474	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$61,707	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$137,138	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$39,960	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$9,403	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$11,351	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$28,791	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	$43,003	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$234,582	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$270,607	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$55,692	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$23,515	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$120,872	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$6,516	CHECK/WIRE
EAST ASIA AND THE PACIFIC	INTERNATIONAL DEVELOPMENT	$70,766	CHECK/WIRE
EAST ASIA AND THE PACIFIC	OTHER	$11,616	CHECK/WIRE
EAST ASIA AND THE PACIFIC	OTHER	$33,622	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PUBLIC HEALTH	$40,000	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PUBLIC HEALTH	$168,331	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PUBLIC HEALTH	$25,411	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PUBLIC HEALTH	$23,251	CHECK/WIRE
EAST ASIA AND THE PACIFIC	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$5,164	CHECK/WIRE
EAST ASIA AND THE PACIFIC	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$33,981	CHECK/WIRE
EAST ASIA AND THE PACIFIC	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$14,890	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$228,281	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$6,805,468	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$685,438	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$625,328	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$100,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$110,095	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$200,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$43,192	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$67,045	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$38,902	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$1,304,428	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$275,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$92,596	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$416,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$248,005	CHECK/WIRE
EUROPE	INTERNATIONAL DEVELOPMENT	$12,000	CHECK/WIRE
EUROPE	OTHER	$14,951	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$72,248	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$61,782	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$15,423	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$88,017	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$119,765	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$51,512	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$604,784	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$67,196	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$110,666	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$69,176	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$22,325	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$88,761	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$74,098	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$363,493	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$272,979	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$23,042	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$83,327	CHECK/WIRE
NORTH AMERICA	ESSENTIAL MEDICINE	$407,985	CHECK/WIRE
NORTH AMERICA	OTHER	$15,000	CHECK/WIRE
NORTH AMERICA	OTHER	$36,813	CHECK/WIRE
NORTH AMERICA	PUBLIC HEALTH	$20,000	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	PUBLIC HEALTH	$14,262	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	PUBLIC HEALTH	$12,765	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	PUBLIC HEALTH	$27,229	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	PUBLIC HEALTH	$22,072	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	PUBLIC HEALTH	$20,104	CHECK/WIRE
SOUTH AMERICA	PUBLIC HEALTH	$9,975	CHECK/WIRE
SOUTH AMERICA	PUBLIC HEALTH	$33,220	CHECK/WIRE
SOUTH AMERICA	PUBLIC HEALTH	$31,364	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	$1,272,450	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	$50,000	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	$197,798	CHECK/WIRE
SOUTH ASIA	INTERNATIONAL DEVELOPMENT	$1,226,892	CHECK/WIRE
SOUTH ASIA	INTERNATIONAL DEVELOPMENT	$1,349,900	CHECK/WIRE
SOUTH ASIA	OTHER	$15,000	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$34,410	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$54,644	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$16,297	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$5,278	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$11,348	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$46,813	CHECK/WIRE
SOUTH ASIA	PUBLIC HEALTH	$8,875	CHECK/WIRE
SOUTH ASIA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$57,691	CHECK/WIRE
SOUTH ASIA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$127,275	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$79,913	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$174,751	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	$175,428	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,777	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$19,496	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$236,307	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$82,391	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$22,339	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,777	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,148	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$19,245	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$16,386	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$92,299	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,683	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$47,293	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$29,468	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$36,760	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$18,672	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$20,228	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,529	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$18,751	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,554	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$61,315	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,573	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$45,848	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$150,668	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$44,200	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$125,190	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$29,958	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,145	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$23,609	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$34,200	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$46,316	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$26,102	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$40,000	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$15,654	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$23,174	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$212,760	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$41,036	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$198,169	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,320	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$67,561	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$26,089	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$53,951	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$79,625	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$37,870	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$19,549	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,379	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$42,009	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$34,679	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$24,653	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$33,694	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,922	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$36,213	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$14,649	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$78,226	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$289,936	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$22,138	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$66,004	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,766	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$22,806	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$31,332	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$14,639	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$22,694	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$20,267	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$16,627	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$72,837	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,764	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$16,707	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,680	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$53,135	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,542	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,807	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$35,207	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,358	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$13,754	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$48,188	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$209,401	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$30,186	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$42,738	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$20,143	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$34,781	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$28,847	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$30,077	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$41,399	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$14,217	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$24,963	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$51,117	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$15,327	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$20,623	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$22,951	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,866	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,912	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,985	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$38,927	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$35,670	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$34,034	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$27,220	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$14,445	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$5,772	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,368	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$25,869	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$16,738	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$31,244	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$33,382	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$29,473	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$21,658	CHECK/WIRE
SUB-SAHARAN AFRICA	INTERNATIONAL DEVELOPMENT	$17,866	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	$10,121	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	$15,000	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	$14,910	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	$14,993	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	$15,000	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$10,554	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$129,152	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$39,983	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$5,155	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$649,519	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$26,005	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$24,949	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$108,390	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$47,538	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$20,339	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$12,491	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$667,124	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$14,700	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$13,530	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$16,298	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$27,202	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$23,108	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$348,050	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$67,394	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$869,863	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$7,843	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$10,862	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$143,315	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$13,706	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$9,420	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$13,569	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$12,525	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$6,092	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$215,669	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$14,796	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$85,190	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$188,757	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$6,200	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$29,964	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$5,473	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$6,817	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$22,064	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$16,130	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$111,833	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$7,800	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$117,000	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$17,795	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$142,511	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$27,934	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$458,478	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$60,427	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$9,560	CHECK/WIRE
SUB-SAHARAN AFRICA	PUBLIC HEALTH	$12,633	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$24,930	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$23,500	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$7,023	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$37,414	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$25,298	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$21,754	CHECK/WIRE
SUB-SAHARAN AFRICA	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$8,842	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	$1,964,380	CHECK/WIRE
EUROPE	INTERNATIONAL DEVELOPMENT	$29,605	CHECK/WIRE
EUROPE	PUBLIC HEALTH	$346,683	CHECK/WIRE
EUROPE	OTHER	$1,943,592	CHECK/WIRE
EUROPE	TECHNOLOGY, DEVELOPMENT & INTRODUCTION	$7,419	CHECK/WIRE

Field	Value	IRS element (for citing)
Total501c3 Org	224	Total501c3OrgCnt
Total Other Org	34	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (1)	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE THAT GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS, AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE REASONABLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH'S ESTABLISHED POLICIES AND PROCEDURES PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (80 entries)

Address Line1USAddress/AddressLine1Txt	Address Line2USAddress/AddressLine2Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
ADVANCED BIOSCIENCE LABORATORIES INC
9800 MEDICAL CENTER DRIVE BUILDING	D	ROCKVILLE	MD	20850	621242262	N/A	$360,270	ESSENTIAL MEDICINE
CHARLES RIVER LABORATORIES ASHLAND LLC
1407 GEORGE ROAD		ASHLAND	OH	44805	760509980	N/A	$215,800	ESSENTIAL MEDICINE
EMORY UNIVERSITY
201 DOWMAN DRIVE		ATLANTA	GA	30322	580566256	501(C)(3)	$49,135	ESSENTIAL MEDICINE
FINA BIOSOLUTIONS LLC
9430 KEY WEST AVE SUITE 200		ROCKVILLE	MD	20850	205448275	N/A	$121,196	ESSENTIAL MEDICINE
FRAUNHOFER USA CENTER FOR MOLECULAR BIOTECHNOLOGY
9 INNOVATION WAY SUITE 200		NEWARK	DE	19711	383203030	501(C)(3)	$800,527	ESSENTIAL MEDICINE
GEORGE WASHINGTON UNIVERSITY
2121 EYE STREET NW		WASHINGTON	DC	20052	530196584	501(C)(3)	$9,549	ESSENTIAL MEDICINE
INTERNATIONAL AIDS VACCINE INITIATIVE
110 WILLIAM ST 27TH FLOOR		NEW YORK	NY	10038	133870223	501(C)(3)	$79,148	ESSENTIAL MEDICINE
JOHNS HOPKINS UNIVERSITY
OFFICE OF RESEARCH ADMIN 615 N	WOLFE STREET W1100	BALTIMORE	MD	21205	131687001	501(C)(3)	$385,461	ESSENTIAL MEDICINE
NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
6610 ROCKLEDGE DRIVE MSC 6612		BETHESDA	MD	20892	520858115	GOV	$971,208	ESSENTIAL MEDICINE
PAN AMERICAN HEALTH ORGANIZATION
525 TWENTY-THIRD STREET NW		WASHINGTON	DC	20037	237072046	501(C)(3)	$10,000	ESSENTIAL MEDICINE
PPD DEVELOPMENT LP
8551 RESEARCH WAY SUITE 90		MIDDLETON	WI	53562	561640186	N/A	$348,684	ESSENTIAL MEDICINE
SAINT LOUIS UNIVERSITY
3700 WEST PINE MALL FUSZ HALL SUITE	357	ST LOUIS	MO	63108	430654872	501(C)(3)	$41,932	ESSENTIAL MEDICINE
SANARIA INC
9800 MEDICAL CENTER DRIVE SUITE	A209	ROCKVILLE	MD	20850	562354362	N/A	$81,624	ESSENTIAL MEDICINE
SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORRY PINES ROAD		LA JOLLA	CA	92037	330435954	501(C)(3)	$749,862	ESSENTIAL MEDICINE
SEATTLE BIOMEDICAL RESEARCH INSTITUTE
307 WESTLAKE AVE N SUITE 500		SEATTLE	WA	98109	910961784	501(C)(3)	$1,724,906	ESSENTIAL MEDICINE
STATE UNIVERSITY OF NEW YORK AT BUFFALO
1300 ELWOOD AVENUE		BUFFALO	NY	14222	160865182	501(C)(3)	$86,441	ESSENTIAL MEDICINE
UNITED STATES NAVAL MEDICAL RESEARCH CENTER
503 ROBERT GRANT AVE		SILVER SPRING	MD	209107500	470100048	GOV	$564,544	ESSENTIAL MEDICINE
UNIVERSITY OF MARYLAND BALTIMORE
PO BOX 41428		BALTIMORE	MD	212036428	526002033	501(C)(3)	$217,780	ESSENTIAL MEDICINE
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE CENTER FOR VACCINE DEVELOPMENT
685 WEST BALTIMORE STREET ROOM 480		BALTIMORE	MD	21201	526002033	501(C)(3)	$115,122	ESSENTIAL MEDICINE
UNIVERSITY OF MIAMI
1320 SOUTH DIXIE HIGHWAY GABLES 1	TOWER SUITE 650	CORAL GABLES	FL	33146	590624458	501(C)(3)	$20,000	ESSENTIAL MEDICINE
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
85 SOUTH PROSPECT STREET WATERMAN	217	BURLINGTON	VT	05405	030179440	501(C)(3)	$90,247	ESSENTIAL MEDICINE
UNIVERSITY OF WASHINGTON (MEDICINE)
750 REPUBLICAN STREET BOX 358061		SEATTLE	WA	981094725	916001537	501(C)(3)	$33,605	ESSENTIAL MEDICINE
WALTER REED ARMY INSTITUTE OF RESEARCH
503 ROBERT GRANT DRIVE		SILVER SPRING	MD	209107500	520664528	GOV	$1,312,578	ESSENTIAL MEDICINE
YALE UNIVERSITY
GRANTS AND CONTRACT FINANCIAL ADMIN	PO BOX 1873	NEW HAVEN	CT	06508	060646973	501(C)(3)	$78,563	ESSENTIAL MEDICINE
FRED HUTCHINSON CANCER RESEARCH CENTER
PO BOX 19024		SEATTLE	WA	98109	237156071	501(C)(3)	$28,311	ESSENTIAL MEDICINE
ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION
1140 CONNECTICUT AVENUE NW		WASHINGTON	DC	20036	954191698	501(C)(3)	$5,796,442	INTERNATIONAL DEVELOPMENT
INITIATIVES INC
264 BEACON STREET		BOSTON	MA	02116	042961350	N/A	$219,800	INTERNATIONAL DEVELOPMENT
JHPIEGO
1615 THAMES STREET		BALTIMORE	MD	21231	237424444	501(C)(3)	$394,031	INTERNATIONAL DEVELOPMENT
WORLD VISION DC
300 I ST NE		WASHINGTON DC	DC	20002	951922279	501(C)(3)	$4,262,214	INTERNATIONAL DEVELOPMENT
AMERICAN ACADEMY OF PEDIATRICS
141 NORTHWEST POINT BLVD		ELK GROVE VILLAGE	IL	600071098	362275597	501(C)(3)	$31,916	OTHER
GLOBAL HEALTH COUNCIL
1875 K STREET NW 4TH FLOOR		WASHINGTON	DC	20006	521048393	501(C)(3)	$8,829	OTHER
GLOBAL HEALTH VISIONS
138 BROADWAY SUITE 1 G		BROOKLYN	NY	11211	261903904	N/A	$62,628	OTHER
JSI RESEARCH & TRAINING INSTITUTE INC
1616 NORTH FORT MYER DRIVE 11TH	FLOOR	ARLINGTON	VA	22209	042578579	N/A	$83,704	OTHER
BASIC HEALTH INTERNATIONAL
ONE GUSTAV L LEVY PLACE PO BOX 1170	1170	NEW YORK	NY	100296574	203408717	501(C)(3)	$185,551	PUBLIC HEALTH
BOSTON UNIVERSITY
ONE SILBER WAY		BOSTON	MA	02215	042103547	501(C)(3)	$17,991	PUBLIC HEALTH
BRAC USA
110 WILLIAM STREET 29TH FLOOR		NEW YORK	NY	10038	208456741	501(C)(3)	$90,277	PUBLIC HEALTH
CHILDFUND INTERNATIONAL
2821 EMERYWOOD PARKWAY		RICHMOND	VA	23294	540536100	501(C)(3)	$5,170	PUBLIC HEALTH
CHRISTIAN CONNECTIONS FOR INTERNATIONAL HEALTH
1329 SHEPARD DRIVE SUITE 6		STERLING	VA	20164	541932761	501(C)(3)	$91,940	PUBLIC HEALTH
ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION
1140 CONNECTICUT AVENUE NW		WASHINGTON	DC	20036	954191698	501(C)(3)	$679,014	PUBLIC HEALTH
EVIDENCE ACTION
641 S ST NW 3RD FL WEWORK		WASHINGTON	DC	20001	900874591	501(C)(3)	$49,523	PUBLIC HEALTH
FAMILY HEALTH INTERNATIONAL 360
359 BLACKWELL ST SUITE 200		DURHAM	NC	27701	237413005	501(C)(3)	$55,981	PUBLIC HEALTH
GEORGETOWN UNIVERSITY INSTITUTE FOR REPRODUCTIVE HEALTH
4301 CONNECTICUT AVENUE NW SUITE	310	WASHINGTON	DC	20008	530196603	501(C)(3)	$42,561	PUBLIC HEALTH
GMMB INC
1200 WESTLAKE AVENUE N SUITE 1005		SEATTLE	WA	98109	521305983	N/A	$51,072	PUBLIC HEALTH
GYNUITY HEALTH PROJECTS LLC
15 EAST 26TH STREET SUITE 801		NEW YORK	NY	10010	061652595	N/A	$18,208	PUBLIC HEALTH
HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH
INTERNATIONAL HEALTH 677 HUNTINGTON	AVENUE	BOSTON	MA	02115	042103580	501(C)(3)	$14,926	PUBLIC HEALTH
HELEN KELLER INTERNATIONAL
352 PARK AVENUE SOUTH 12TH FLOOR		NEW YORK	NY	10010	135562162	501(C)(3)	$115,357	PUBLIC HEALTH
INTRAHEALTH INTERNATIONAL
6340 QUADRANGLE DRIVE SUITE 200		CHAPEL HILL	NC	27514	550825466	501(C)(3)	$86,301	PUBLIC HEALTH
IPAS
PO BOX 9990		CHAPEL HILL	NC	27515	561071085	501(C)(3)	$15,256	PUBLIC HEALTH
JSI RESEARCH & TRAINING INSTITUTE INC
1616 NORTH FORT MYER DRIVE 11TH	FLOOR	ARLINGTON	VA	22209	042578579	N/A	$7,788	PUBLIC HEALTH
KYBELE INC
3524 YADKINVILLE ROAD 124		WINSTON SALEM	NC	27106	900759003	501(C)(3)	$654,140	PUBLIC HEALTH
LIGER MEDICAL
1316 E UTAH HIGHLANDS DRIVE		LEHI	UT	84043	320361779	N/A	$36,050	PUBLIC HEALTH
MANAGEMENT SCIENCES FOR HEALTH
200 RIVERS EDGE DRIVE SUITE 320		MEDFORD	MA	02155	042482188	501(C)(3)	$23,938	PUBLIC HEALTH
MEDICAL CARE DEVELOPMENT INC
8401 COLESVILLE ROAD SUITE 425		SILVER SPRING	MD	20910	016022787	501(C)(3)	$2,172,823	PUBLIC HEALTH
PATHFINDER INTERNATIONAL
NINE GALEN STREET SUITE 217		WATERTOWN	MA	02472	530235320	501(C)(3)	$238,337	PUBLIC HEALTH
POPULATION COUNCIL
4301 CONNECTICUT AVENUE NW SUITE	280	WASHINGTON	DC	20008	131687001	501(C)(3)	$88,846	PUBLIC HEALTH
POPULATION SERVICES INTERNATIONAL
1120 19TH STREET NW SUITE 600		WASHINGTON	DC	20036	560942853	501(C)(3)	$1,868,489	PUBLIC HEALTH
SAVE THE CHILDREN FEDERATION INC
501 KINGS HIGHWAY E SUITE 400		FAIRFIELD	CT	06825	060726487	501(C)(3)	$368,137	PUBLIC HEALTH
TULANE UNIVERSITY SCHOOL OF PUBLIC HEALTH AND TROPICAL MEDICINE
1440 CANAL ST		NEW ORLEANS	LA	70112	720423889	501(C)(3)	$264,880	PUBLIC HEALTH
UNITED NATIONS FUND FOR POPULATION ACTIVITIES
220 EAST 42ND STREET		NEW YORK	NY	10017		GOV	$12,339	PUBLIC HEALTH
VILLAGEREACH
2900 EASTLAKE AVE E SUITE 230		SEATTLE	WA	98102	912083484	501(C)(3)	$15,450	PUBLIC HEALTH
BECTON DICKINSON
ONE BECTON DRIVE		FRANKLIN LAKES	NJ	07417	220761201	N/A	$450,800	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
BOSTON UNIVERSITY
ONE SILBER WAY		BOSTON	MA	02215	042103547	501(C)(3)	$37,263	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
CASCADE DESIGNS INC
4000 FIRST AVENUE SOUTH		SEATTLE	WA	98134	910969695	N/A	$154,782	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
CONRAD
1911 NORTH FORT MYER DRIVE		ARLINGTON	VA	22209	237053028	501(C)(3)	$280,649	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
FRED HUTCHINSON CANCER RESEARCH CENTER
PO BOX 19024		SEATTLE	WA	98109	237156071	501(C)(3)	$6,000	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
JOHN SNOW INC
44 FARNSWORTH STREET		BOSTON	MA	02210	042578580	N/A	$25,434	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
KARL WEYRAUCH DBA PYGMY SURVIVAL ALLIANCE
4545 49TH AVE NE		SEATTLE	WA	98105	270438932	501(C)(3)	$6,000	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
OVERLAKE HOSPITAL MEDICAL CENTER
1035 116TH AVE NE		BELLEVUE	WA	98004	910652651	501(C)(3)	$42,449	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
PUBLIC HEALTH INSTITUTE
555 12TH STREET 10TH FLOOR		OAKLAND	CA	946074046	941646278	501(C)(3)	$651,856	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORRY PINES ROAD		LA JOLLA	CA	92037	330435954	501(C)(3)	$305,191	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
SEATTLE CHILDREN'S HOSPITAL
4800 SAND POINT WAY NE		SEATTLE	WA	98105	910564748	501(C)(3)	$6,945	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
SOLAR ELECTRIC LIGHT FUND
1612 K STREET NW SUITE 300		WASHINGTON	DC	20006	521701564	501(C)(3)	$210,000	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
TUFTS UNIVERSITY
136 HARRISON AVENUE		BOSTON	MA	02111	042103634	501(C)(3)	$94,636	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
505 PARNASSUS AVENUE		SAN FRANCISCO	CA	94143	946036493	501(C)(3)	$55,999	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
UNIVERSITY OF WASHINGTON
4333 BROOKLYN AVE NE BOX 359472		SEATTLE	WA	98195	916001537	501(C)(3)	$1,215,722	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
UNIVERSITY OF WISCONSIN
21 N PARK STREET SUITE 6401		MADISON	WI	53705	396006492	501(C)(3)	$30,139	TECHNOLOGY, DEVELOPMENT & INTRODUCTION
PATH VACCINE SOLUTIONS
2201 WESTLAKE AVE SUITE 200		SEATTLE	WA	98121	830431851	501(C)(3)	$282,029	OTHER
PATH DRUG SOLUTIONS
2201 WESTLAKE AVE SUITE 200		SEATTLE	WA	98121	943384500	501(C)(3)	$163,077	OTHER
LOYOLA UNIVERSITY CHICAGO
6339 N SHERIDAN ROAD		CHICAGO	IL	60660	361408475	501(C)(3)	-$70,493	ESSENTIAL MEDICINE
FAMILY CARE INTERNATIONAL INC
45 BROADWAY SUITE 320		NEW YORK	NY	10006	237413005	501(C)(3)	-$47,708	PUBLIC HEALTH

Field	Value	IRS element (for citing)
Total501c3 Org	59	Total501c3OrgCnt
Total Other Org	14	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (2 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt
TECHNOLOGY, DEVELOPMENT & INTRODUCTION	1	$16,300
OTHER	1	$12,700

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE THAT GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE REASONABLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Idemnification Gross Up Pmts	Yes (X)	IdemnificationGrossUpPmtsInd
Housing Allowance Or Residence	Yes (X)	HousingAllowanceOrResidenceInd
Written Policy Ref T And E Expnss	Yes (1)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (1)	SubstantiationRequiredInd
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (1)	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
STEPHEN B DAVIS
PRESIDENT AND CEO	$475,514	$0	$143,338	$0	$4,421	$0	$31,800	$0	$30,241	$0	$685,314	$0	$0	$0
OLIVIA D POLIUS
CHIEF FINANCIAL OFFICER	$301,435	$0	$0	$0	$1,950	$0	$31,541	$0	$17,264	$0	$352,190	$0	$0	$0
DANIEL LASTER
COO AND GENERAL COUNSEL	$302,682	$0	$0	$0	$1,900	$0	$31,800	$0	$11,094	$0	$347,476	$0	$0	$0
DAVID C KASLOW
VP - PRODUCT DEVELOPMENT	$350,433	$0	$0	$0	$4,421	$0	$31,800	$0	$31,692	$0	$418,346	$0	$0	$0
AMIE E BATSON
CHIEF STRATEGY OFFICER	$292,301	$0	$0	$0	$1,265	$0	$26,034	$0	$816	$0	$320,416	$0	$0	$0
KATHY CAHILL
VP - INTERNATIONAL DEVELOPMENT	$272,175	$0	$0	$0	$0	$0	$31,800	$0	$4,805	$0	$308,780	$0	$0	$0
DAVID W FLEMING
VP - PUBLIC HEALTH	$267,868	$0	$0	$0	$0	$0	$31,800	$0	$16,192	$0	$315,860	$0	$0	$0
KATHRYN A O'DRISCOLL
CHIEF HUMAN RESOURCES OFFICER	$235,469	$0	$0	$0	$1,800	$0	$27,151	$0	$16,408	$0	$280,828	$0	$0	$0
MARK D MURRAY
VP - GLOBAL ENGAGEMENT	$251,681	$0	$0	$0	$1,650	$0	$31,442	$0	$24,155	$0	$308,928	$0	$0	$0
JOHN SKIBIAK
ASSOCIATE DIRECTOR	$157,809	$0	$0	$0	$291,861	$0	$25,078	$0	$46,449	$0	$521,197	$0	$0	$0
JAMES B MCKENNA
ASSOCIATE DIRECTOR	$142,288	$0	$0	$0	$233,468	$0	$20,324	$0	$39,484	$0	$435,564	$0	$0	$0
TRAD M HATTON
CHIEF OF PARTY	$124,213	$0	$0	$0	$190,032	$0	$16,188	$0	$23,023	$0	$353,456	$0	$0	$0
RIKKA E TRANGSRUD
COUNTRY PROGRAM LEADER	$184,450	$0	$0	$0	$108,422	$0	$20,581	$0	$15,137	$0	$328,590	$0	$0	$0
DAVID A SHOULTZ
GLOBAL PROGRAM LEADER	$255,418	$0	$0	$0	$28,010	$0	$31,647	$0	$25,126	$0	$340,201	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 1A	HOUSING ALLOWANCE & TAX INDEMNIFICATION ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT.
PART I, LINE 7	BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II).

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	ALTIMETRIK CORPORATION	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Relationship Description	ALTIMETRIK IS CONTROLLED BY RAJENDRA VATTIKUTI, PATH BOARD MEMBER	RelationshipDescriptionTxt
Transaction	$210,080	TransactionAmt
Transaction	PATH PURCHASED SERVICES FROM ALTIMETRIK DURING THE YEAR	TransactionDesc
Sharing Of Revenues	0	SharingOfRevenuesInd

Schedule M IRS990ScheduleM

Books And Publications BooksAndPublicationsGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Noncash Contributions Rpt F990	$3,925	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Cars And Other Vehicles CarsAndOtherVehiclesGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	1	ContributionCnt
Noncash Contributions Rpt F990	$5,324	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	27	ContributionCnt
Noncash Contributions Rpt F990	$1,147,189	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	SUPPLIES	Desc
Contribution	3	ContributionCnt
Noncash Contributions Rpt F990	$1,835	NoncashContributionsRptF990Amt
Method Of Determining Revenues	COST OR SALES PRICE	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Form8283 Received	0	Form8283ReceivedCnt
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (1)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, COLUMN (B):	FormAndLineReferenceDesc
Explanation	THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1	AN INTERNATIONAL NONPROFIT ORGANIZATION, WE SAVE LIVES AND IMPROVE HEALTH, ESPECIALLY AMONG WOMEN AND CHILDREN. WE ACCELERATE INNOVATION ACROSS FIVE PLATFORMS-VACCINES, DRUGS, DIAGNOSTICS, DEVICES, AND SYSTEM AND SERVICE INNOVATIONS-THAT HARNESS OUR ENTREPRENEURIAL INSIGHT, SCIENTIFIC AND PUBLIC HEALTH EXPERTISE, AND PASSION FOR HEALTH EQUITY. BY MOBILIZING PARTNERS AROUND THE WORLD, WE TAKE INNOVATION TO SCALE, WORKING ALONGSIDE COUNTRIES PRIMARILY IN AFRICA AND ASIA TO TACKLE THEIR GREATEST HEALTH NEEDS. TOGETHER, WE DELIVER MEASURABLE RESULTS THAT DISRUPT THE CYCLE OF POOR HEALTH. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE REACHED AN AVERAGE OF 150 MILLION PEOPLE PER YEAR WITH LIFESAVING HEALTH SOLUTIONS. OUR FUNDERS AND COLLABORATORS SPAN THE PUBLIC, PRIVATE, AND NONPROFIT SECTORS AND ARE PIVOTAL TO OUR SUCCESS. THEIR CONTRIBUTIONS SUPPORT OUR WIDE-REACHING WORK TO ACCELERATE INNOVATION FROM IDEA TO IMPACT.
FORM 990, PART III, LINE 4A	IN 2016, PATH WON AN IMPORTANT RENEWAL FOR THE MAXIMISING THE QUALITY OF SCALING UP NUTRITION (MQSUN) PROJECT, WHICH BUILDS UPON OUR PREVIOUS EFFORTS. THROUGH MQSUN, PATH LEADS A CONSORTIUM OF FIVE ORGANIZATIONS TO EXPAND THE EVIDENCE BASE ON THE CAUSES OF UNDERNUTRITION, ENHANCE THE SKILLS AND CAPACITY OF PARTICIPATING MQSUN GOVERNMENTS TO SCALE UP NUTRITION-RELATED PROGRAMS, AND PROVIDE TECHNICAL GUIDANCE ON PROGRAM DESIGN, IMPLEMENTATION, AND MONITORING AND EVALUATION. PATH ALSO CONTINUED EFFORTS TO SCALE UP USE OF HUMAN MILK BANKS SO NEWBORNS AND INFANTS BENEFIT FROM BREAST MILK EVEN WHEN THEIR MOTHERS ARE UNABLE TO BREASTFEED. MILK BANKS USE DONATED EXTRA MILK FROM LACTATING MOTHERS, PASTEURIZE IT TO MAKE IT SAFE, AND FREEZE IT UNTIL IT IS NEEDED. IN 2016, A PRIVATE FAMILY FOUNDATION AWARDED PATH FUNDING FOR A TWO-YEAR PROJECT TO EXPAND ACCESS TO AND INTAKE OF HUMAN MILK. THE MAKING EVERY BABY COUNT INITIATIVE STRENGTHENS LEADERSHIP AND CAPACITY AT THE NATIONAL AND LOCAL LEVELS TO MANAGE AND SUSTAIN BEST PRACTICES IN NEWBORN CARE. IN 2016, PATH SUPPORTED GHANA'S CENTRAL GOVERNMENT AND REGIONS TO REDUCE NEONATAL MORTALITY THROUGH SPECIFIC ACTIVITIES THAT IMPROVED AND STANDARDIZED NEWBORN CARE. SEXUAL AND REPRODUCTIVE HEALTH: PATH'S WORK IN SRH IS GUIDED BY KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL WOMEN. BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS WOMEN'S DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS. PATH HAS LONG APPRECIATED THE ROLE THAT COMMERCIAL PHARMACIES AND DRUG SHOPS PLAY IN DELIVERING PRIMARY HEALTH CARE. IN 2016, WE CONDUCTED A REVIEW OF PATH'S HISTORIC WORK IN THIS AREA AND CURRENT STRATEGY OF ENGAGING DRUG SHOPS AND PHARMACIES IN THE PROVISION OF LOW-COST, HIGH-QUALITY SRH PRODUCTS AND SERVICES. THIS EFFORT SPECIFICALLY HIGHLIGHTED OPPORTUNITIES FOR PATH TO WORK MORE ACTIVELY, AND WITH KEY PLAYERS, TO IMPROVE AND EXPAND SRH SERVICES, PARTICULARLY AMONG YOUNG WOMEN IN THE DRC AND UGANDA. WE ALSO CONCLUDED COUNTRY-LED PILOT INTRODUCTIONS OF A NEW FORM OF INJECTABLE CONTRACEPTION, SUBCUTANEOUS DEPOT MEDROXYPROGESTERONE ACETATE (DMPA-SC, SOLD BY PFIZER INC. AS SAYANA PRESS ). THIS PRODUCT COMBINES A LOWER-DOSE FORMULATION OF THE WIDELY USED CONTRACEPTIVE DEPO-PROVERA WITH THE PATH-DEVELOPED UNIJECT INJECTION SYSTEM. DURING THE PILOT PERIOD (2014-2016), NEARLY HALF A MILLION UNITS WERE ADMINISTERED IN BURKINA FASO, NIGER, SENEGAL, AND UGANDA. DMPA-SC WAS ADMINISTERED TO APPROXIMATELY 135,000 WOMEN USING MODERN CONTRACEPTION FOR THE FIRST TIME. THE SUCCESS OF THESE PILOTS MEANT THAT ALL FOUR COUNTRIES BEGAN MOVING FORWARD WITH PRODUCT SCALE-UP OR EXPANSION IN THEIR NATIONAL FAMILY PLANNING PROGRAMS. PATH ALSO COMPLETED RESEARCH ON SELF-INJECTION OF DMPA-SC IN SENEGAL AND UGANDA. THESE STUDIES, CO-LED BY THE SENEGAL AND UGANDA MINISTRIES OF HEALTH, LED TO GOVERNMENT DECISIONS TO PILOT SELF-INJECTION OUTSIDE OF A RESEARCH SETTING IN BOTH COUNTRIES. [SAYANA PRESS AND DEPO-PROVERA ARE REGISTERED TRADEMARKS OF PFIZER INC. UNIJECT IS A TRADEMARK OF BD.] PATH WORKED WITH PARTNERS WORLDWIDE AND IN SEVERAL COUNTRIES TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL CANCER, WHICH IS MOST OFTEN CAUSED BY INFECTION WITH HPV. WE PARTNERED WITH COMPANIES TO DEVELOP NEW DEVICES TO IMPROVE PRECANCER TREATMENT IN LMIC. WE PARTNERED WITH THE MINISTRIES OF HEALTH IN GUATEMALA, HONDURAS, AND NICARAGUA TO INTRODUCE AND QUICKLY SCALE UP HPV TESTING FOR PRIMARY CERVICAL CANCER SCREENING. THIS METHOD ENABLES WOMEN TO COLLECT THEIR OWN SAMPLES FOR SCREENING, REDUCING BOTTLENECKS IN THE HEALTH CARE SYSTEM AND OVERCOMING CULTURAL BARRIERS TO INTIMATE EXAMS. TO COMBAT BREAST CANCER, WE WORKED WITH THE NATIONAL CANCER INSTITUTE IN PERU TO DEVELOP MATERIALS FOR TRAINING NURSES AND VOLUNTEERS TO SERVE AS PATIENT NAVIGATORS FOR WOMEN AND THEIR FAMILIES. IN 2016, PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 400 PUBLIC, PRIVATE, AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO SUPPLIES, SERVICES, AND OPTIONS FOR PREVENTING UNINTENDED PREGNANCY AND SEXUALLY TRANSMITTED INFECTIONS. DIGITAL HEALTH SOLUTIONS: PATH USES INFORMATION AND COMMUNICATION TECHNOLOGIES TO IMPROVE HEALTH AND SAVE LIVES. IN 2016, OUR GROWING DIGITAL HEALTH TEAM APPLIED ITS EXPERTISE TO AN INCREASING NUMBER OF PROJECTS. KEY ACCOMPLISHMENTS INCLUDED SUPPORTING THE GOVERNMENT OF TANZANIA TO IMPROVE COUNTRYWIDE HEALTH SERVICES AND OUTCOMES. WE ALSO WORKED WITH THE US GOVERNMENT TO START A DIGITAL HEALTH INITIATIVE FOCUSED ON COORDINATING INVESTMENTS IN PROVEN TECHNOLOGIES AND ON COMMUNITY STRENGTHENING. WE ALSO COLLABORATED WITH THE JOINT LEARNING NETWORK FOR UNIVERSAL HEALTH COVERAGE TO PUBLISH A TOOLKIT OFFERING STEP-BY-STEP GUIDANCE ON USING DATA ANALYTICS TO MONITOR HEALTH PROVIDER PAYMENT SYSTEMS. THE BID INITIATIVE, A COLLABORATION BETWEEN PATH AND THE GOVERNMENTS OF TANZANIA AND ZAMBIA, EMPOWERS COUNTRY GOVERNMENTS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. IN 2016, WE CONTINUED TO IMPLEMENT DATA USE AND DATA QUALITY INTERVENTIONS IN BOTH COUNTRIES. THESE INCLUDED ELECTRONIC IMMUNIZATION REGISTRIES, SUPPLY CHAIN MANAGEMENT, DATA USE CAMPAIGNS, AND OTHER INTERVENTIONS THAT PUT THE POWER OF DATA INTO THE HANDS OF HEALTH WORKERS. THESE TOOLS AND PRACTICES WILL HELP HEALTH WORKERS TRACK AND IMPROVE CHILDREN'S IMMUNIZATIONS AND OTHER SERVICES. NONCOMMUNICABLE DISEASES: PATH IS AT THE FOREFRONT OF THE FIGHT IN LMIC AGAINST NCDS, INCLUDING DIABETES, CARDIOVASCULAR DISEASE, AND WOMEN'S CANCERS, WHICH ARE RESPONSIBLE FOR AN ALARMING TWO-THIRDS OF DEATHS WORLDWIDE. ALMOST 75 PERCENT OF THESE DEATHS OCCUR IN LOWER-RESOURCE SETTINGS. IN 2016, WE CONTINUED TO BUILD THE FOUNDATIONS OF OUR NEW AND EXPANDING NCD PROGRAM. YEARS OF ADVOCACY AND RELATIONSHIP-BUILDING PAID OFF IN 2016 WHEN PATH WAS SELECTED TO IMPLEMENT A FIRST-OF-ITS-KIND PROGRAM THAT INTEGRATES SCREENING AND CARE FOR HYPERTENSION INTO HIV/AIDS SERVICES IN KENYA. LEADERS IN KENYA AND SENEGAL, AS PART OF PATH'S "NO EMPTY SHELVES: DIABETES SUPPLIES, THERE WHEN NEEDED" PROJECT, PARTICIPATED IN COMPREHENSIVE SUPPLY CHAIN ASSESSMENTS, INCLUDING AN EVALUATION OF THE PRICE AND AVAILABILITY OF DIABETES ESSENTIAL MEDICINES AND TECHNOLOGIES IN PUBLIC AND PRIVATE FACILITIES. WE ALSO OFFICIALLY LAUNCHED OUR COMMUNITIES FOR HEALTHY HEARTS PROGRAM IN HO CHI MINH CITY, VIETNAM. BY THE END OF 2016, THE PROJECT HAD DEVELOPED AND PILOTED A WEB-BASED SOFTWARE PROGRAM TO FACILITATE SCREENING, FOLLOW-UP REFERRALS, AND CASE MANAGEMENT, AND HAD SCREENED 6,809 PEOPLE. FINALLY, WE CONTINUED TO LEAD AND CONTRIBUTE TO CONVENINGS TO RAISE AWARENESS OF AND ORCHESTRATE ACTION TO IMPROVE THE ACCESSIBILITY OF PREVENTION AND CARE FOR PEOPLE AT RISK FOR OR LIVING WITH NCDS. HEALTH SYSTEMS INNOVATION AND DELIVERY: PATH'S HEALTH SYSTEMS ANALYTICS (HSA) UNIT PROMOTES SYSTEMS THINKING IN THE DESIGN, IMPLEMENTATION, SCALE, AND EVALUATION OF HEALTH PROGRAMS AND TECHNOLOGIES. WITHIN AND OUTSIDE OF PATH, THE UNIT PERFORMS SYSTEMATIC, LANDSCAPE, ECONOMIC, AND POLICY ANALYSES; BUILDS NETWORKS OF COLLABORATION AND KNOWLEDGE EXCHANGE; AND SERVES AS A TECHNICAL RESOURCE. IN 2016, HSA WORKED WITH PARTNERS TO SYNTHESIZE A REVIEW OF GLOBAL HEALTH STRATEGIES THAT COULD BE ADOPTED FOR LOW-RESOURCE COMMUNITIES IN THE UNITED STATES. WITH THE ACCESS DELIVERY PARTNERSHIP, WE CONTINUED TO LAY THE FOUNDATION NECESSARY FOR LMIC TO INTEGRATE NEW HEALTH TECHNOLOGIES INTO THEIR HEALTH SYSTEMS. PATH ALSO CONTINUED TO EXPAND OUR GLOBAL HEALTH SECURITY PORTFOLIO. THE EMERGENCE AND RE-EMERGENCE OF HUMAN AND ANIMAL DISEASES HAVE ATTRACTED GROWING ATTENTION AND GENERATED NEW INVESTMENTS IN INNOVATIVE APPROACHES TO IMPROVE THE WORLD'S CAPACITY TO PREVENT, DETECT, AND RESPOND TO OUTBREAKS. IN 2016, WITH THE SUPPORT OF THE US CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), PATH CONTINUED TO WORK WITH NATIONAL LEADERS IN SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR PUBLIC HEALTH SYSTEMS AND BUILD THEIR CAPACITY, AND PREPARED FOR A NEW PARTNERSHIP WITH THE DRC. WE ALSO PREPARED TO LAUNCH OUR NEW EPIDEMIC PREPAREDNESS AND RESPONSE/GLOBAL HEALTH SECURITY INNOVATION HEALTH INNOVATION TEAM. THE GOAL OF THIS NEW TEAM WILL BE TO CREATE A SET OF STRATEGIES TO INCREASE PATH'S ABILITY TO PROTECT VULNERABLE POPULATIONS AGAINST PUBLIC HEALTH EMERGENCIES. PLANNED INITIATIVES INCLUDE DEVELOPING AND INTRODUCING INNOVATIONS TO STRENGTHEN ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING NOVEL VACCINE PLATFORMS, PREPARING MEDICAL COUNTERMEASURES FOR PANDEMIC INFLUENZA, AND DEFINING PATH'S ROLE IN COMBATTING ANTIMICROBIAL RESISTANCE.
FORM 990, PART III, LINE 4A	NUTRITION INNOVATION: RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, OUR NUTRITION INNOVATION INITIATIVE CONTINUED TO DRIVE INNOVATIVE APPROACHES TO ADDRESS THE MASSIVE BURDEN OF STUNTING, WASTING, AND VITAMIN AND MINERAL DEFICIENCIES IN COMMUNITIES AROUND THE WORLD BY BRINGING TOGETHER GLOBAL HEALTH, DEVELOPMENT, AND CONSERVATION ORGANIZATIONS. ACTING AS AN INCUBATOR FOR IDEAS, PATH PARTNERED IN 2016 WITH A SMALL FOR-PROFIT ENTERPRISE AND COMMUNITIES IN GHANA TO SCALE FARMING OF AFRICAN PALM WEEVIL LARVAE, OR AKOKONO. THESE LARVAE ARE A LOW-COST SOURCE OF HIGH-QUALITY PROTEIN, FAT, AND NUTRIENTS THAT CHILDREN NEED TO STAY HEALTHY, AND THIS TYPE OF FARMING HAS A LOW ENVIRONMENTAL FOOTPRINT. IN NORTHERN SENEGAL, WE WORKED TO DESIGN INFANT AND YOUNG CHILD NUTRITION INTERVENTIONS INFORMED BY CAREGIVERS AND LOCAL PRACTICES AND EXPLORED HOW TO EXPAND THE ARRAY OF BENEFICIAL MICROORGANISMS IN LOCALLY FERMENTED MILK PRODUCTS TO ENRICH THE DIETS OF YOUNG CHILDREN AND REDUCE DIARRHEAL INCIDENCE. WE ALSO CONTINUED TO DRIVE MULTISECTOR COLLABORATION IN 2016 BY WORKING TO ESTABLISH THE BRIDGE COLLABORATIVE. THIS IS A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT TO ENGAGE MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS IN DEVELOPING A TOOLKIT TO GUIDE FUTURE MULTIDISCIPLINARY PROGRAMMING. IN ADDITION, THE NUTRITION INNOVATION TEAM WAS PART OF A NUMBER OF PRESENTATIONS AT INTERNATIONAL FORUMS AND PUBLISHED SEVERAL GROUNDBREAKING STUDIES, ADVANCING INNOVATIVE THINKING ON BROAD, EFFECTIVE SOLUTIONS.
FORM 990, PART III, LINE 4C	PATH HAS ALSO SUPPORTED POLICIES TO EXPAND ZAMBIAN WOMEN'S ACCESS TO FAMILY PLANNING SERVICES BY ALLOWING COMMUNITY HEALTH WORKERS TO ADMINISTER INJECTABLE CONTRACEPTIVES. PATH FIRST GATHERED EVIDENCE TO SUPPORT THE CHANGE, THEN MET WITH MOH OFFICIALS TO PRESENT THIS INFORMATION. THE MOH ANNOUNCED IN 2016 THAT IT WOULD ALLOW TRAINED COMMUNITY-BASED HEALTH CARE WORKERS TO ADMINISTER INJECTABLES.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN.
FORM 990, PART VI, SECTION B, LINE 12C	PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING.
FORM 990, PART VI, SECTION B, LINE 15	THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE LAST MAJOR REVIEW WAS COMPLETED IN 2014 WHEN PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. THE NEXT REVIEW WILL BE IN 2017. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE VICE PRESIDENTS AND EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE.
FORM 990, PART VI, SECTION C, LINE 19	PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE.
FORM 990, PART XI, LINE 9:	FROM TIME TO TIME, UNSPENT AWARD FUNDS (OR UNUSED OBLIGATIONS) MAY BE RETURNED TO A FUNDER FOR A VARIETY OF REASONS INCLUDING, BUT NOT LIMITED TO, EARLY TERMINATION OF A PROJECT BY A FUNDER OR A REDUCTION IN FUNDS REQUIRED TO ACCOMPLISH A PROJECT'S SCOPE OF WORK. -13,751,105.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Exempt Code SectionExemptCodeSectionTxt	Public Charity StatusPublicCharityStatusTxt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt	Controlled OrganizationControlledOrganizationInd	Address Line1ForeignAddress/AddressLine1Txt	CityForeignAddress/CityNm	CountryForeignAddress/CountryCd	Legal Domicile Foreign CountryLegalDomicileForeignCountryCd
PATH VACCINE SOLUTIONS
2201 WESTLAKE AVENUE	SEATTLE	WA	98109	830431851	ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN	WA	501(C)(3)	LINE 12A, I	PATH	Yes (1)
PATH DRUG SOLUTIONS
280 UTAH AVENUE SUITE 250	SAN FRANCISCO	CA	94080	943384500	DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES	CA	501(C)(3)	LINE 12A, I	PATH	Yes (1)
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
					EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH		501(C)(3)		PATH	Yes (1)	207 ROUTE DE FERNEY 1218 LE GRAND-S	GENEVA	SZ	SZ

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	0	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	Yes (1)	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	Yes (1)	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	0	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	0	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	0	DivRelatedOrganizationInd
Asset Sale To Other Org	0	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	0	AssetPurchaseFromOtherOrgInd
Asset Exchange	0	AssetExchangeInd
Rental Of Facilities To Oth Org	0	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	0	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	0	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	0	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	0	SharingOfFacilitiesInd
Paid Employees Sharing	0	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	0	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	0	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	0	TransferToOtherOrgInd
Transfer From Other Org	0	TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (6 entries)

Transaction TypeTransactionTypeTxt	InvolvedInvolvedAmt	Method Of Amount DeterminationMethodOfAmountDeterminationTxt
PATH VACCINE SOLUTIONS
C	$15,502,397	FMV
PATH VACCINE SOLUTIONS
B	$282,029	FMV
PATH DRUG SOLUTIONS
C	$2,358,006	FMV
PATH DRUG SOLUTIONS
B	$163,077	FMV
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
C	$1,503,451	FMV
FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
B	$4,291,680	FMV